

Highly Enantioselective Synthesis of Chiral 7-Ring O- and N-Heterocycles by a One-pot Nitro-Michael/Cyclization Tandem Reaction

Renate Rohlmann, Constantin-Gabriel Daniliuc, Olga García Mancheño*

*Westfälischen Wilhelms-Universität Münster, Organisch-Chemisches Institut, Corrensstraße 40,
D-48149 Münster (Germany). Fax: (0049) 251 83 33202.*

E-mail: olga.garcia@uni-muenster.de

Supporting Information

Contents

General information and materials	S1
Experimental procedures and characterization	S2
Synthesis of the aldehyde precursors 9a and 9b	S2
General procedure for the O- and N-allylation or propargylation	S3
Analytical data for compounds 10a-s	S3
General procedures for the synthesis of nitroolefins 2	S8
Analytical data for compounds 2a-s	S9
Optimization and general procedure for the enantioselective nitro-Michael addition	S14
Analytical data for compound 4a	S14
Optimization and general procedure for the nitrile cycloaddition reaction	S16
General procedure for the one-pot reaction	S16
Analytical data for compounds 5	S17
Proposed mechanism and analytical data for the conjugated nitriles 6 side-products	S42
Synthesis of bioactive compound ent-8	S43
References	S48
X-Ray ORTEP and data of compound 5a	S49
NMR Spectra of compounds	S50


General information and materials. NMR spectra were acquired on a Bruker ARX-300 and a Varian AV-300 or AV-400 MHz. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CHCl_3 , 7.26 ppm for ^1H NMR and 77.16 ppm for ^{13}C NMR) and spin-spin coupling constants (J) are given in Hz. ^{13}C NMR spectra were acquired on a broad band decoupled mode. Mass spectra were recorded on a Micromass LCT spectrometer using electrospray ionisation (ESI^+) techniques. Analytical thin layer chromatography (TLC) was performed using pre-coated aluminium-backed plates (Merck Kieselgel 60 F254) and visualised by ultraviolet irradiation or KMnO_4 dip. Infrared spectra were recorded on a Varian Associated FT-IR 3100

Excalibur. The wave numbers (ν) of recorded IR-signals are quoted in cm^{-1} . Optical rotations, $[\alpha]_{\text{D}}^{20}$, were measured on a Perkin-Elmer 241 polarimeter. The enantiomeric excess (*ee*) of the products was determined by chiral stationary phase HPLC (Daicel Chiralpak IA, IC and AD-H or Daicel Chiralcel OD-H columns). Catalysts **1a-d**, **1e**² and **1f**³ were prepared according to reported procedures in the literature.


X-Ray diffraction: Data sets were collected with a Nonius KappaCCD diffractometer. Programs used: data collection, COLLECT (Nonius B.V., 1998); data reduction Denzo-SMN (Z. Otwinowski, W. Minor, *Methods Enzymol.* **1997**, 276, 307-326); absorption correction, Denzo (Z. Otwinowski, D. Borek, W. Majewski, W. Minor, *Acta Crystallogr.* **2003**, A59, 228-234); structure solution SHELXS-97 (G. M. Sheldrick, *Acta Crystallogr.* **1990**, A46, 467-473); structure refinement SHELXL-97 (G. M. Sheldrick, *Acta Crystallogr.* **2008**, A64, 112-122) and graphics, XP (BrukerAXS, 2000). Thermals ellipsoids are shown with 30% probability, *R*-values are given for observed reflections, and *wR*² values are given for all reflections.

Experimental procedures and characterization:


Synthesis of the aldehyde precursors **9a** and **9b**⁴



N-(2-Formylphenyl)benzamide (**9a**)⁵


 2-Aminobenzyl alcohol (2.00 g, 16.24 mmol, 1.0 equiv.) and Et₃N (2.7 mL, 19.45 mmol, 1.2 equiv.) was dissolved in 50 mL of dry THF. Benzoyl chloride (2.1 mL, 17.86 mmol, 1.1 equiv.) was slowly added. After stirring the reaction mixture for 12 h at room temperature, the solvent was removed in vacuo and the residue was dissolved in ethylacetate, washed with saturated NaHCO₃ (aq.) and dried over MgSO₄. Without further purification the alcohol was dissolved in 250 mL CH₂Cl₂ and treated with pyridinium chlorochromate (4.20 g, 19.45 mmol, 1.2 equiv.). After full oxidation to the aldehyde, the reaction mixture was filtrated over a celite pad and the solvent removed in vacuo. The residue was purified by column chromatography (pentane-EtOAc: 15:1 → 9:1) affording *N*-(2-formylphenyl)benzamide (**9a**) (3.25 g, 14.45 mmol, 89%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ = 12.07 (s, 1H), 9.96 (d, *J* = 0.8 Hz, 1H), 8.94 (d, *J* = 8.5 Hz, 1H), 8.08 – 8.03 (m, 2H), 7.69 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.64 (ddd, *J* = 8.8, 7.4, 1.7 Hz, 1H), 7.59 – 7.48 (m, 3H), 7.28 – 7.19 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 196.0, 166.1, 141.3, 136.4, 136.3, 134.4, 132.3, 129.0 (2C), 127.6 (2C), 123.1, 122.0, 120.0; HRMS (ESI⁺): calculated for C₁₄H₁₁NO₂+Na⁺ [*M*+Na]⁺: *m/z* = 248.0682, found 248.0685.

N-(2-Formylphenyl)-4-methylbenzenesulfonamide (**9b**)⁴

 2-Aminobenzyl alcohol (2.00 g, 16.24 mmol, 1.0 equiv.) and pyridine (1.6 mL, 19.81 mmol, 1.2 equiv.) was dissolved in 60 mL of dry CHCl₃. 4-Toluenesulfonyl chloride (3.44 g, 17.86 mmol, 1.1 equiv.) was dissolved in 60 mL CHCl₃ and slowly added. After stirring the

reaction mixture for 12 h at room temperature, the solvent was removed in vacuo and the residue was dissolved in ethylacetate, washed with saturated NaHCO₃ (aq.) and dried over MgSO₄. Without further purification the alcohol was dissolved in 250 mL CH₂Cl₂ and treated with pyridinium chlorochromate (4.20 g, 19.45 mmol, 1.2 equiv.). After full oxidation to the aldehyde, the reaction mixture was filtrated over a celite pad and the solvent removed in vacuo. The residue was purified by column chromatography (pentane-EtOAc: 15:1→9:1) affording *N*-(2-formylphenyl)-4-methylbenzenesulfonamide (**9b**) (4.24 g, 15.43 mmol, 95%) as a white solid. ¹H NMR (300 MHz, CDCl₃): δ = 10.79 (s, 1H), 9.82 (d, *J* = 0.7 Hz, 1H), 7.80 – 7.72 (m, 2H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.59 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.50 (ddd, *J* = 8.6, 7.4, 1.6 Hz, 1H), 7.23 (dd, *J* = 8.2, 0.9 Hz, 2H), 7.16 (td, *J* = 7.5, 1.0 Hz, 1H), 2.36 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 195.1, 144.3, 140.0, 136.4, 136.2, 135.9, 129.9, 127.4, 123.1, 122.0, 117.8, 21.7; HRMS (ESI⁺) calculated for C₁₄H₁₃NO₃S+Na⁺ [M+Na]⁺: *m/z* = 298.0508, found 298.0508.

General procedure for the O- and N-allylation or propargylation⁵



An ordinary vial equipped with a magnetic stirring bar was charged with aldehyde **9** (1 equiv.) and K₂CO₃ (1.1 equiv.) in DMF (0.6 M). To the stirring solution allyl bromide or propargyl bromide (1.1 equiv.) was added dropwise. After stirring the solution for 2 days water was added and extracted 3 times with Et₂O. The combined organic phases was dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography.

2-Allyloxy benzaldehyde (**10a**)⁵


Following the general procedure, salicylaldehyde (3.00 g, 24.56 mmol, 1.0 equiv.) was treated with K₂CO₃ (3.73 g, 27.02 mmol, 1.1 equiv.) and allyl bromide (2.40 mL, 27.02 mmol, 1.1 equiv.) in 30 mL DMF. The 2-allyloxy benzaldehyde (**10a**) was isolated by distillation (1 Torr, 90 °C) as colorless oil (3.82 g, 23.53 mmol, 96%). ¹H NMR (300 MHz, CDCl₃): δ = 10.53 (d, *J* = 0.8 Hz, 1H), 7.83 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.52 (ddd, *J* = 8.4, 7.3, 1.9 Hz, 1H), 7.13 – 6.88 (m, 2H), 6.20 – 5.94 (m, 1H), 5.44 (dq, *J* = 17.3, 1.6 Hz, 1H), 5.33 (dq, *J* = 10.6, 1.4 Hz, 1H), 4.65 (dt, *J* = 5.1, 1.6 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 189.8, 161.0, 136.0, 132.5, 128.5, 125.1, 120.9, 118.1, 112.9, 69.2; HRMS (ESI⁺) calculated for C₁₀H₁₀O₂+Na⁺ [M+Na]⁺: *m/z* = 85.0573, found 85.0571.

2-(Allyloxy)-5-methylbenzaldehyde (**10e**)⁶


Following the general procedure, 5-methylsalicylaldehyde (855 mg, 6.28 mmol, 1.0 equiv.) was treated with K₂CO₃ (927 mg, 6.71 mmol, 1.1 equiv.) and allyl bromide

(530 μ L, 6.71 mmol, 1.1 equiv.) in DMF (10 mL). The 2-(allyloxy)-5-methylbenzaldehyde (**10e**) was isolated by column chromatography (petane-EtOAc 400:3) as colorless oil (916 mg, 5.20 mmol, 83%). **¹H NMR** (300 MHz, CDCl₃): δ = 10.50 (s, 1H), 7.64 (dd, J = 2.5, 1.0 Hz, 1H), 7.33 (ddd, J = 8.5, 2.1, 1.0 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H), 6.07 (ddt, J = 17.2, 10.4, 5.1 Hz, 1H), 5.44 (dq, J = 17.2, 1.6 Hz, 1H), 5.32 (dq, J = 10.6, 1.4 Hz, 1H), 4.63 (dt, J = 5.0, 1.4 Hz, 2H), 2.31 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃): δ = 190.1, 159.2, 136.6, 132.7, 130.4, 128.6, 124.9, 118.1, 113.0, 69.4, 20.4. **HRMS** (ESI⁺): calculated for C₁₁H₁₂O₂+Na⁺ [M+Na]⁺: m/z = 199.0730, found 199.0732.


2-(Allyloxy)-5-methoxybenzaldehyde (**10f**)

 Following the general procedure, 5-methoxysalicylaldehyde (1.12 g, 7.35 mmol, 1.0 equiv.) was treated with K₂CO₃ (1.10 g, 7.85 mmol, 1.1 equiv.) and allyl bromide (670 μ L, 7.85 mmol, 1.1 equiv.) in DMF (10 mL). The 2-(allyloxy)-5-methoxybenzaldehyde (**10f**) was isolated by column chromatography (petane-EtOAc 400:3) as colorless oil (1.41 mg, 7.34 mmol, 99%). **¹H NMR** (400 MHz, CDCl₃): δ = 10.47 (s, 1H), 7.30 (d, J = 3.3 Hz, 1H), 7.08 (dd, J = 9.1, 3.3 Hz, 1H), 6.91 (d, J = 9.1 Hz, 1H), 6.03 (ddt, J = 17.3, 10.4, 5.2 Hz, 1H), 5.40 (dq, J = 17.3, 1.6 Hz, 1H), 5.29 (dq, J = 10.6, 1.4 Hz, 1H), 4.58 (dt, J = 5.2, 1.6 Hz, 2H), 3.77 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃): δ = 189.5, 155.8, 153.8, 132.7, 125.4, 123.5, 118.0, 114.9, 110.3, 70.0, 55.8; **HRMS** (ESI⁺) calculated for C₁₁H₁₂O₃+Na⁺ [M+Na]⁺: m/z = 215.0679, found 215.0686.

2-(Allyloxy)-4-methoxybenzaldehyde (**10g**)⁶


 Following the general procedure, 4-methoxysalicylaldehyde (500 mg, 3.29 mmol, 1.0 equiv.) was treated with K₂CO₃ (499 mg, 3.61 mmol, 1.1 equiv.) and allyl bromide (313 μ L, 3.61 mmol, 1.1 equiv.) in DMF (5 mL). The 2-(allyloxy)-4-methoxybenzaldehyde (**10g**) was isolated by column chromatography (petane-EtOAc 9:1) as colorless oil (620 mg, 3.23 mmol, 98%). **¹H NMR** (300 MHz, CDCl₃): δ = 10.35 (d, J = 0.8 Hz, 1H), 7.82 (d, J = 8.7 Hz, 1H), 6.55 (ddd, J = 8.7, 2.2, 0.8 Hz, 1H), 6.43 (d, J = 2.2 Hz, 1H), 6.07 (ddt, J = 17.3, 10.4, 5.1 Hz, 1H), 5.45 (dq, J = 17.3, 1.6 Hz, 1H), 5.33 (dq, J = 10.5, 1.4 Hz, 1H), 4.62 (dt, J = 5.1, 1.6 Hz, 2H), 3.86 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃): δ = 188.3, 166.0, 162.6, 132.3, 130.5, 119.2, 118.1, 106.0, 99.0, 69.1, 55.6; **HRMS** (ESI⁺) calculated for C₁₁H₁₂O₃+Na⁺ [M+Na]⁺: m/z = 215.0679, found 215.0688.

2-(Allyloxy)-5-methoxybenzaldehyde (**10h**)⁵

 Following the general procedure, 3-methoxysalicylaldehyde (1.09 g, 7.14 mmol, 1.0 equiv.) was treated with K₂CO₃ (1.10 g, 7.85 mmol, 1.1 equiv.) and allyl bromide (670 μ L, 7.85 mmol, 1.1 equiv.) in DMF (10 mL). The 2-(allyloxy)-5-methoxybenzaldehyde (**10h**) was isolated by column chromatography (petane-EtOAc 400:3→400:14) as colorless oil (1.31 g, 6.82 mmol, 95%). **¹H NMR** (400 MHz, CDCl₃): δ = 10.42 (d, J = 0.8 Hz, 1H), 7.39 (dd, J = 6.9, 2.5 Hz, 1H), 7.17 – 7.04 (m,


2H), 6.05 (ddt, $J = 17.1, 10.3, 6.1$ Hz, 1H), 5.33 (dq, $J = 17.2, 1.5$ Hz, 1H), 5.24 (dq, $J = 10.3, 1.2$ Hz, 1H), 4.64 (dt, $J = 6.1, 1.3$ Hz, 2H), 3.88 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 190.5, 153.1, 151.3, 133.2, 130.2, 124.2, 119.1, 119.0, 118.0, 75.2, 56.1$; HRMS (ESI^+): calculated for $\text{C}_{11}\text{H}_{12}\text{O}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 215.0679$, found 215.0689.

2-(Allyloxy)-4-diethylaminobenzaldehyde (10i)




Following the general procedure, 4-diethylaminosalicylaldehyde (1.00 g, 5.17 mmol, 1.0 equiv.) was treated with K_2CO_3 (786 mg, 5.69 mmol, 1.1 equiv.) and allyl bromide (490 μL , 5.69 mmol, 1.1 equiv.) in DMF (8 mL). The 2-(allyloxy)-4-diethylaminobenzaldehyde (**10i**) was isolated by column chromatography (petane-EtOAc 9:1) as a yellow solid (1.20 g, 5.14 mmol, 99%). ^1H NMR (300 MHz, CDCl_3): $\delta = 10.20$ (s, 1H), 7.72 (d, $J = 8.9$ Hz, 1H), 6.37 – 6.22 (m, 1H), 6.07 (ddt, $J = 17.5, 10.4, 5.1$ Hz, 2H), 5.45 (dq, $J = 17.3, 1.6$ Hz, 1H), 5.32 (dq, $J = 10.4, 1.4$ Hz, 1H), 4.63 (dt, $J = 5.2, 1.6$ Hz, 2H), 3.41 (q, $J = 7.1$ Hz, 4H), 1.21 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 187.2, 163.3, 133.1$ (2C), 130.5 (2C), 117.8 (2C), 104.8, 69.1, 45.2 (2C), 12.7 (2C); HRMS (ESI^+) calculated for $\text{C}_{14}\text{H}_{19}\text{NO}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 256.1208$, found 256.1309.

2-(Allyloxy)-1-naphthaldehyde (10j)⁵



Following the general procedure, 2-hydroxy-1-naphthaldehyde (2.00 g, 11.62 mmol, 1.0 equiv.) was treated with K_2CO_3 (1.77 g, 12.78 mmol, 1.1 equiv.) and allyl bromide (1.10 mL, 142.78 mmol, 1.1 equiv.) in DMF (18 mL). 2-(allyloxy)-1-naphthaldehyde (**10j**) was isolated by column chromatography (petane-EtOAc 9:1) as a white solid (2.44 g, 11.50 mmol, 99%). ^1H NMR (300 MHz, CDCl_3): $\delta = 10.95$ (s, 1H), 9.28 (dd, $J = 8.8, 1.0$ Hz, 1H), 8.03 (dt, $J = 9.1, 0.6$ Hz, 1H), 7.77 (ddt, $J = 8.2, 1.4, 0.6$ Hz, 1H), 7.62 (ddd, $J = 8.6, 6.9, 1.5$ Hz, 1H), 7.42 (ddd, $J = 8.1, 6.9, 1.2$ Hz, 1H), 7.26 (d, $J = 9.1$ Hz, 1H), 6.10 (ddt, $J = 17.3, 10.4, 5.1$ Hz, 1H), 5.48 (dtd, $J = 17.2, 1.7, 1.2$ Hz, 1H), 5.36 (dq, $J = 10.6, 1.4$ Hz, 1H), 4.79 (dt, $J = 5.1, 1.6$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 192.2, 163.2, 137.6, 132.4, 131.7, 130.0, 128.7, 128.3, 125.1, 125.0, 118.5, 117.2, 113.9, 70.3$; HRMS (ESI^+) calculated for $\text{C}_{14}\text{H}_{12}\text{O}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 235.0730$, found 235.0737.


2-(Allyloxy)-5-fluorobenzaldehyde (10k)⁵




Following the general procedure, 5-fluorobenzaldehyde (1.00 g, 7.14 mmol, 1.0 equiv.) was treated with K_2CO_3 (1.10 g, 7.85 mmol, 1.1 equiv.) and allyl bromide (670 μL , 7.85 mmol, 1.1 equiv.) in DMF (10 mL). The 2-(allyloxy)-5-fluorobenzaldehyde (**10k**) was isolated by column chromatography (petane-EtOAc 400:5) as colorless oil (1.89 g, 6.60 mmol, 93%). ^1H NMR (300 MHz, CDCl_3): $\delta = 10.48$ (d, $J = 3.2$ Hz, 1H), 7.51 (dd, $J = 8.3, 3.3$ Hz, 1H), 7.23 (ddd, $J = 9.1, 7.6, 3.3$ Hz, 1H), 6.95 (dd, $J = 9.1, 3.9$ Hz, 1H), 6.06 (ddt, $J = 17.1, 10.5, 5.2$ Hz, 1H), 5.44 (dq, $J = 17.3, 1.6$ Hz, 1H), 5.35 (dq, $J = 10.5, 1.4$ Hz, 1H), 4.64 (dt, $J = 5.3, 1.5$ Hz, 2H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 188.8$ (d, $^4J = 1.8$ Hz),

157.4 (d, $^4J = 1.5$ Hz), 157.1 (d, $^1J = 241.5$ Hz), 132.3, 126.0 (d, $^3J = 6.1$ Hz), 122.6 (d, $^2J = 23.9$ Hz), 118.5, 114.7 (d, $^3J = 7.2$ Hz), 114.2 (d, $^2J = 23.4$ Hz), 70.0; **^{19}F NMR** (282 MHz, CDCl_3): $\delta = -122.33$; **HRMS** (ESI^+) calculated for $\text{C}_{10}\text{H}_9\text{FO}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 203.0479$, found 203.0483.


2-(Allyloxy)-5-bromobenzaldehyde (**10l**)⁵

 Following the general procedure, 5-bromosalicylaldehyde (1.44 g, 7.14 mmol, 1.0 equiv.) was treated with K_2CO_3 (1.10 g, 7.85 mmol, 1.1 equiv.) and allyl bromide (670 μL , 7.85 mmol, 1.1 equiv.) in DMF (10 mL). The 2-(allyloxy)-5-bromobenzaldehyde (**10l**) was isolated by column chromatography (petane-EtOAc 400:3) as a yellow solid (1.67 g, 6.93 mmol, 97%). **^1H NMR** (400 MHz, CDCl_3): $\delta = 10.41$ (s, 1H), 7.89 (d, $J = 2.7$ Hz, 1H), 7.57 (dd, $J = 8.9, 2.6$ Hz, 1H), 6.86 (d, $J = 8.9$ Hz, 1H), 6.04 (ddt, $J = 17.3, 10.4, 5.2$ Hz, 1H), 5.42 (dq, $J = 17.2, 1.6$ Hz, 1H), 5.33 (dq, $J = 10.6, 1.4$ Hz, 1H), 4.63 (dt, $J = 5.2, 1.6$ Hz, 2H); **^{13}C NMR** (100 MHz, CDCl_3): $\delta = 188.3, 159.9, 138.3, 132.0, 131.0, 126.4, 118.6, 115.0, 113.7, 69.6$; **HRMS** (ESI^+) calculated for $\text{C}_{10}\text{H}_9\text{BrO}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 262.9678$, found 262.9677.


2-(Allyloxy)-4,6-dichlorobenzaldehyde (**10m**)⁵

 Following the general procedure, 4,6-dichlorosalicylaldehyde (701 mg, 3.67 mmol, 1.0 equiv.) was treated with K_2CO_3 (558 mg, 4.04 mmol, 1.1 equiv.) and allyl bromide (350 μL , 4.04 mmol, 1.1 equiv.) in DMF (6 mL). The 2-(allyloxy)-4,6-dichlorobenzaldehyde (**10m**) was isolated by column chromatography (petane-EtOAc 400:3) as colorless oil (796 mg, 3.44 mmol, 94%). **^1H NMR** (400 MHz, CDCl_3): $\delta = 10.47$ (s, 1H), 7.06 (dd, $J = 1.9, 0.5$ Hz, 1H), 6.89 (d, $J = 1.8$ Hz, 1H), 6.03 (ddt, $J = 17.3, 10.6, 5.1$ Hz, 1H), 5.48 (dtd, $J = 17.3, 1.7, 1.1$ Hz, 1H), 5.37 (dq, $J = 10.6, 1.4$ Hz, 1H), 4.64 (dt, $J = 5.1, 1.6$ Hz, 2H); **^{13}C NMR** (100 MHz, CDCl_3): $\delta = 188.0, 161.5, 140.4, 137.3, 131.4, 123.5, 121.2, 119.0, 112.5, 70.2$; **HRMS** (ESI^+) calculated for $\text{C}_{10}\text{H}_8\text{Cl}_2\text{O}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 252.9794$, found 252.9800.

N-Allyl-*N*-(2-formylphenyl)benzamide (**10n**)⁵


 Following the general procedure, *N*-(2-formylphenyl)benzamide **8a** (1.00 g, 4.44 mmol, 1.0 equiv.) was treated with K_2CO_3 (675 mg, 4.88 mmol, 1.1 equiv.) and allyl bromide (420 μL , 4.88 mmol, 1.1 equiv.) in DMF (7.5 mL). The *N*-allyl-*N*-(2-formylphenyl)benzamide (**10n**) was isolated by column chromatography (petane-DCM-EtOAc 2:1:0.1) as colorless oil (1.11 g, 4.17 mmol, 94%). **^1H NMR** (400 MHz, CDCl_3): $\delta = 10.05$ (s, 1H), 7.70 (d, $J = 7.8$ Hz, 1H), 7.54 (t, $J = 7.8$ Hz, 1H), 7.34 (d, $J = 7.8$ Hz, 1H), 7.28 – 7.07 (m, 6H), 6.00 (dd, $J = 16.9, 8.8$ Hz, 1H), 5.14 (t, $J = 14.6$ Hz, 2H), 4.55 (ddd, $J = 69.0, 14.0, 6.4$ Hz, 2H); **^{13}C NMR** (100 MHz, CDCl_3): $\delta = 189.4, 170.5, 145.0, 135.3, 134.9$ (2C), 132.4, 132.0, 130.3, 130.1 (2C), 129.9, 128.6, 128.1, 128.0, 119.7, 54.2; **HRMS** (ESI^+) calculated for $\text{C}_{17}\text{H}_{15}\text{NO}_2 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 288.0995$, found 288.0993.

N-Allyl-*N*-(2-formylphenyl)-4-methylbenzenesulfonamide (**10o**)⁵




Following the general procedure, salicylaldehyde (1.30 g, 4.72 mmol, 1.0 equiv.) was treated with K_2CO_3 (717 mg, 5.19 mmol, 1.1 equiv.) and allyl bromide (500 μL , 5.19 mmol, 1.1 equiv.) in DMF (7.5 mL). The *N*-allyl-*N*-(2-formylphenyl)-4-methylbenzenesulfonamide (**10o**) was isolated by column chromatography (petane-DCM-EtOAc 2:1:0.1) as a white solid (1.44 g, 4.57 mmol, 97%). ^1H NMR (400 MHz, CDCl_3): δ = 10.40 (s, 1H), 8.04 – 7.77 (m, 1H), 7.51 – 7.33 (m, 4H), 7.34 – 7.14 (m, 2H), 6.67 (dd, J = 7.7, 1.4 Hz, 1H), 5.70 (ddt, J = 16.9, 10.2, 6.8 Hz, 1H), 5.20 – 4.88 (m, 2H), 4.56 (br.s, 1H), 3.81 (br.s, 1H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 190.2, 144.3, 141.3, 136.0, 134.2, 134.1, 131.6, 129.7 (2C), 128.6, 128.3, 127.9 (2C), 127.8, 120.5, 54.3, 21.6; HRMS (ESI⁺) calculated for $\text{C}_{17}\text{H}_{17}\text{NO}_3\text{S}+\text{Na}^+$ $[\text{M}+\text{Na}]^+$: m/z = 338.0821, found 338.0817.

2-(Prop-2-yn-1-yloxy)benzaldehyde (**10p**)⁷




Following the general procedure, salicylaldehyde (1.00 g, 8.19 mmol, 1.0 equiv.) was treated with K_2CO_3 (1.00 mL, 9.01 mmol, 1.1 equiv.) and propargyl bromide (80% in toluene; 1.00 mL, 9.01 mmol, 1.1 equiv.) in DMF (13 mL). The 2-(prop-2-yn-1-yloxy)benzaldehyde (**7l**) was isolated by column chromatography (petane-DCM 5:3) as colorless oil (1.28 g, 7.99 mmol, 98%). ^1H NMR (300 MHz, CDCl_3): δ = 10.47 (s, 1H), 7.85 (dd, J = 7.7, 1.9 Hz, 1H), 7.56 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.08 (ddt, J = 14.2, 7.5, 1.0 Hz, 2H), 4.82 (d, J = 2.4 Hz, 2H), 2.57 (t, J = 2.4 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ = 189.6, 159.8, 135.8, 128.6, 125.5, 121.8, 113.3, 77.8, 76.6, 56.4; HRMS (ESI⁺) calculated for $\text{C}_{10}\text{H}_8\text{O}_2+\text{Na}^+$ $[\text{M}+\text{Na}]^+$: m/z = 183.0417, found 183.0420.

5-Methyl-2-(prop-2-yn-1-yloxy)benzaldehyde (**10q**)⁶



Following the general procedure, 5-methylsalicylaldehyde (739 mg, 5.43 mmol, 1.0 equiv.) was treated with K_2CO_3 (825 mg, 5.97 mmol, 1.1 equiv.) and propargyl bromide (80% in toluene; 0.67 mL, 5.97 mmol, 1.1 equiv.) in DMF (4.7 mL). The 2-(allyloxy)-5-methylbenzaldehyde (**10q**) was isolated by column chromatography (petane-EtOAc 20:1) as a yellow solid (696 mg, 4.00 mmol, 74%). ^1H NMR (300 MHz, CDCl_3): δ = 10.44 (s, 1H), 7.71 – 7.57 (m, 1H), 7.36 (ddd, J = 8.5, 2.4, 0.8 Hz, 1H), 7.01 (d, J = 8.5 Hz, 1H), 4.79 (d, J = 2.4 Hz, 2H), 2.55 (t, J = 2.4 Hz, 1H), 2.31 (t, J = 0.7 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ = 189.8, 158.0, 136.5, 131.3, 128.7, 125.3, 113.4, 78.0, 76.5, 56.6, 20.4; HRMS (ESI⁺): calculated for $\text{C}_{11}\text{H}_{10}\text{O}_2+\text{Na}^+$ $[\text{M}+\text{Na}]^+$: m/z = 197.0573, found 197.0586.


5-Methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde (**10r**)⁶



Following the general procedure, 5-methoxysalicylaldehyde (974mg, 6.40mmol, 1.0 equiv.) was treated with K_2CO_3 (973 mg, 7.04 mmol, 1.1 equiv.) and propargyl bromide (80% in toluene; 0.82 mL, 7.04 mmol, 1.1 equiv.) in DMF (5 mL). The 2-


(allyloxy)-5-methylbenzaldehyde (**10r**) was isolated by column chromatography (petane-EtOAc 20:1) as a yellow solid (1.14 g, 6.01 mmol, 64%). ¹H NMR (300 MHz, CDCl₃): δ = 10.44 (s, 1H), 7.34 (d, *J* = 3.2 Hz, 1H), 7.14 (dd, *J* = 9.1, 3.1 Hz, 1H), 7.07 (d, *J* = 9.0 Hz, 1H), 4.78 (d, *J* = 2.4 Hz, 2H), 3.80 (s, 3H), 2.55 (t, *J* = 2.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ = 189.5, 154.6, 154.5, 126.2, 123.4, 115.7, 110.5, 78.0, 76.5, 57.5, 55.9; HRMS (ESI⁺) calculated for C₁₁H₁₀O₂+Na⁺ [M+Na]⁺: *m/z* = 213.0522, found 213.0532.

5-Chloro-2-(prop-2-yn-1-yloxy)benzaldehyde (**10s**)⁶




Following the general procedure, 5-chlorosalicylaldehyde (1.00 g, 6.40 mmol, 1.0 equiv.) was treated with K₂CO₃ (973 mg, 7.04 mmol, 1.1 equiv.) and propargyl bromide (80% in toluene; 0.82 mL, 7.04 mmol, 1.1 equiv.) in DMF (5 mL). The 2-(allyloxy)-5-methylbenzaldehyde (**7b**) was isolated by column chromatography (petane-EtOAc 20:1) as a yellow solid (1.14 g, 6.01 mmol, 64%). ¹H NMR (300 MHz, CDCl₃): δ = 10.39 (s, 1H), 7.79 (d, *J* = 2.8 Hz, 1H), 7.50 (dd, *J* = 8.9, 2.8 Hz, 1H), 7.08 (d, *J* = 8.9 Hz, 1H), 4.82 (d, *J* = 2.4 Hz, 2H), 2.59 (t, *J* = 2.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ = 188.3, 158.2, 135.3, 128.2, 127.5, 126.4, 115.1, 77.3, 77.1, 56.8; HRMS (ESI⁺) calculated for C₁₀H₇O₂+Na⁺ [M+Na]⁺: *m/z* = 217.0027, found 217.0027.


General procedures for the synthesis of nitroolefins **2**



Method A:⁸ Aldehyde **10** (1.0 equiv.) was treated with MeNO₂ (1 equiv.) and 10 M NaOH aq. solution (1.1 equiv.) in MeOH (4 M) at 0 °C for 15 min. Nitroolefin **2** was then isolated by column chromatography.




Method B:⁹ Aldehyde **10** (1.0 equiv.) was treated with MeNO₂ (12.1 equiv.), AcOH (2.9 equiv.) and NH₄OAc (2.2 equiv.) at rt under ultrasound irradiation for 3 h. The nitroolefin **2** was then isolated by column chromatography.




Method C:⁹ Aldehyde **10** (1.0 equiv.) was treated with nitromethane (18.7 equiv.), diisopropylethylamine (0.1 equiv.) and NH₄OAc (2.5 equiv.) at rt under ultrasound irradiation for 3 h. The generated crude alcohol was treated in CH₂Cl₂ (0.1 M) with Ac₂O (1.1 equiv.) in the presence of 4-dimethylaminopyridine (0.05 equiv.) for 24 h. The nitroolefin **2** was then isolated by column chromatography.


(E)-1-(Allyloxy)-2-(2-nitrovinyl)benzene (2a)¹⁰

 Following the general procedure **A**, aldehyde **10a** (3.80 g, 23.42 mmol, 1.0 equiv.) was treated with nitromethane (1.26 mL, 23.42 mmol, 1.0 equiv.) and 10 M NaOH aq. solution (2.6 mL, 25.76 mmol, 1.1 equiv.) in MeOH (6 mL). The corresponding nitroolefin **2a** was isolated by column chromatography (petane-DCM 4:1) as a yellow solid (2.80 g, 13.60 mmol, 58%). ¹H NMR (300 MHz, CDCl₃): δ = 8.17 (d, *J* = 13.6 Hz, 1H), 7.88 (d, *J* = 13.6 Hz, 1H), 7.54 – 7.35 (m, 2H), 7.07 – 6.90 (m, 2H), 6.10 (ddt, *J* = 17.1, 10.6, 5.4 Hz, 1H), 5.44 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.37 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.68 (dt, *J* = 5.5, 1.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 158.6, 138.4, 135.6, 133.5, 132.5, 132.3, 121.4, 119.4, 119.0, 112.6, 69.5; HRMS (ESI⁺) calculated for C₁₁H₁₁NO₃+Na⁺ [M+Na]⁺: *m/z* = 228.0631, found 228.0636.


(E)-1-(Allyloxy)-4-methyl-2-(2-nitrovinyl)benzene (2e)

 Following the general procedure **B**, aldehyde **10e** (916 mg, 5.20 mmol, 1.0 equiv.) was treated with nitromethane (3.40 mL, 63.00 mmol, 12.1 equiv.), acetic acid (0.86 mL, 15.08 mmol, 2.9 equiv.) and NH₄OAc (882 mg, 11.44 mmol, 2.2 equiv.). The corresponding nitroolefin **2e** was isolated by column chromatography (petane-EtOAc 98:2→7:1) as a yellow solid (990 mg, 4.52 mmol, 87%). ¹H NMR (300 MHz, CDCl₃): δ = 8.14 (d, *J* = 13.6 Hz, 1H), 7.87 (d, *J* = 13.6 Hz, 1H), 7.26 – 7.19 (m, 2H), 6.86 (d, *J* = 8.3 Hz, 1H), 6.08 (ddt, *J* = 17.3, 10.6, 5.4 Hz, 1H), 5.42 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.35 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.64 (dt, *J* = 5.4, 1.5 Hz, 2H), 2.31 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 156.6, 138.2, 135.8, 134.1, 132.7, 132.5, 130.7, 119.1, 118.7, 112.6, 69.6, 20.4; HRMS (ESI⁺) calculated for C₁₂H₁₃NO₃+Na⁺ [M+Na]⁺: *m/z* = 242.0788, found 242.0785.

(E)-1-(Allyloxy)-4-methoxy-2-(2-nitrovinyl)benzene (2f)


 Following the general procedure **B**, aldehyde **10f** (1.41 g, 7.34 mmol, 1.0 equiv.) was treated with nitromethane (4.80 mL, 88.78 mmol, 12.1 equiv.), acetic acid (1.20 mL, 21.28, 2.9 equiv.) and NH₄OAc (1.24 g, 16.14 mmol, 2.2 equiv.). The corresponding nitroolefin **2f** was isolated by column chromatography (petane-DCM 4:1→3:1) as a yellow solid (1.46 mg, 6.20 mmol, 85%). ¹H NMR (300 MHz, CDCl₃): δ = 8.14 (d, *J* = 13.6 Hz, 1H), 7.85 (d, *J* = 13.6 Hz, 1H), 7.02 – 6.86 (m, 3H), 6.08 (ddt, *J* = 17.3, 10.6, 5.4 Hz, 1H), 5.42 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.34 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.62 (dt, *J* = 5.4, 1.5 Hz, 2H), 3.80 (s, 3H); ¹³C NMR (75MHz, CDCl₃): δ = 153.8, 153.0, 138.6, 135.4, 132.6, 120.0, 119.3, 118.7, 116.1, 114.0, 70.1, 56.0; HRMS (ESI) calculated for C₁₂H₁₃NO₄+Na⁺ [M+Na]⁺: *m/z* = 258.0737, found 258.0739.

(E)-1-(Allyloxy)-5-methoxy-2-(2-nitrovinyl)benzene (2g)

 Following the general procedure **B**, aldehyde **10g** (620 mg, 3.20 mmol, 1.0 equiv.) was treated with nitromethane (2.10 mL, 39.03 mmol, 12.1 equiv.), acetic acid (0.53 mL, 9.28 mmol, 2.9 equiv.) and NH₄OAc (543 mg, 7.04 mmol, 2.2 equiv.). The


corresponding nitroolefin **2g** was isolated by column chromatography (petane-DCM 5:1→3:1→1:1) as a yellow solid (685 mg, 2.91 mmol, 91%). **¹H NMR** (300 MHz, CDCl₃): δ = 8.12 (d, *J* = 13.5 Hz, 1H), 7.84 (d, *J* = 13.5 Hz, 1H), 7.39 (d, *J* = 8.6 Hz, 1H), 6.56 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.48 (d, *J* = 2.3 Hz, 1H), 6.10 (ddt, *J* = 17.3, 10.7, 5.4 Hz, 1H), 5.44 (dq, *J* = 17.2, 1.5 Hz, 1H), 5.38 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.65 (dt, *J* = 5.4, 1.4 Hz, 2H), 3.86 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃): δ = 164.4, 160.3, 136.2, 135.9, 134.4, 132.2, 119.1, 112.7, 106.3, 99.9, 69.7, 55.8; **HRMS** (ESI⁺) calculated for C₁₂H₁₃NO₄+Na⁺ [M+Na]⁺: *m/z* = 258.0737, found 258.0742.

(*E*)-1-(Allyloxy)-6-methoxy-2-(2-nitrovinyl)benzene (2h)




Following the general procedure **B**, aldehyde **10h** (1.31 g, 6.80 mmol, 1.0 equiv.) was treated with nitromethane (4.45 mL, 82.28 mmol, 12.1 equiv.), acetic acid (1.11 mL, 19.72 mmol, 2.9 equiv.) and NH₄OAc (1.15 mg, 14.96 mmol, 2.2 equiv.). The corresponding nitroolefin **2h** was isolated by column chromatography (petane-DCM 4:1) as a yellow solid (1.17 mg, 4.97 mmol, 73%). **¹H NMR** (300 MHz, CDCl₃): δ = 8.22 (d, *J* = 13.7 Hz, 1H), 7.75 (d, *J* = 13.7 Hz, 1H), 7.14 – 6.98 (m, 3H), 6.07 (ddt, *J* = 17.1, 10.3, 6.1 Hz, 1H), 5.37 (dq, *J* = 17.1, 1.5 Hz, 1H), 5.27 (dq, *J* = 10.3, 1.1 Hz, 1H), 4.60 (dt, *J* = 6.1, 1.3 Hz, 2H), 3.89 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃): δ = 153.3, 148.1, 138.5, 135.0, 133.3, 124.6, 124.6, 121.3, 119.1, 115.8, 74.5, 56.0; **HRMS** (ESI⁺) calculated for C₁₂H₁₃NO₄+Na⁺ [M+Na]⁺: *m/z* = 258.0737, found 258.0738.

(*E*)-1-(Allyloxy)-5-diethylamino-2-(2-nitrovinyl)benzene (2i)



Following the general procedure **B**, aldehyde **10i** (933 mg, 4.00 mmol, 1.0 equiv.) was treated with nitromethane (2.62 mL, 48.40 mmol, 12.1 equiv.), acetic acid (0.66 mL, 11.60 mmol, 2.9 equiv.) and NH₄OAc (678 mg, 8.80 mmol, 2.2 equiv.). The corresponding nitroolefin **2i** was isolated by column chromatography (petane-DCM 7:3→1:1) as a yellow solid (1.02 mg, 3.68 mmol, 92%). **¹H NMR** (300 MHz, CDCl₃): δ = 8.11 (d, *J* = 13.2 Hz, 1H), 7.77 (d, *J* = 13.2 Hz, 1H), 7.25 (d, *J* = 9.0 Hz, 1H), 6.29 (dd, *J* = 8.9, 2.4 Hz, 1H), 6.18 – 6.00 (m, 2H), 5.44 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.35 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.65 (dt, *J* = 5.5, 1.5 Hz, 2H), 3.41 (q, *J* = 7.1 Hz, 4H), 1.21 (t, *J* = 7.1 Hz, 6H). **¹³C NMR** (75 MHz, CDCl₃): δ = 161.1, 152.3, 137.0, 134.8, 132.8, 132.7, 118.6, 107.3, 105.1, 94.9, 69.3, 45.0, 12.7; **HRMS** (ESI⁺) calculated for C₁₅H₂₀N₂O₃+Na⁺ [M+Na]⁺: *m/z* = 299.1366, found 299.1367.


(*E*)-2-(Allyloxy)-1-(2-nitrovinyl)naphthalene (2j)




Following the general procedure **B**, aldehyde **10j** (620 mg, 3.20 mmol, 1.0 equiv.) was treated with nitromethane (2.62 mL, 48.40 mmol, 12.1 equiv.), acetic acid (0.66 mL, 11.60 mmol, 2.9 equiv.) and NH₄OAc (678 mg, 8.80 mmol, 2.2 equiv.). The corresponding nitroolefin **2j** was isolated by column chromatography (petane-DCM 7:1) as a yellow solid (932 mg,

3.65 mmol, 91%). **¹H NMR** (400 MHz, CDCl₃): δ = 8.84 (d, *J* = 13.3 Hz, 1H), 8.24 – 8.10 (m, 2H), 7.94 (d, *J* = 9.1 Hz, 1H), 7.90 – 7.76 (m, 1H), 7.61 (ddd, *J* = 8.5, 6.9, 1.4 Hz, 1H), 7.44 (ddd, *J* = 8.0, 6.9, 1.0 Hz, 1H), 7.28 (d, *J* = 9.2 Hz, 1H), 6.14 (ddt, *J* = 17.3, 10.6, 5.4 Hz, 1H), 5.47 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.40 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.84 (dt, *J* = 5.4, 1.5 Hz, 2H); **¹³C NMR** (100 MHz, CDCl₃): δ = 158.1, 140.5, 134.3, 133.5, 132.3, 131.0, 129.1, 129.1, 128.6, 124.7, 122.4, 119.3, 113.5, 112.0, 70.2; **HRMS** (ESI⁺) calculated for C₁₅H₁₃NO₃+Na⁺ [M+Na]⁺: *m/z* = 278.0788, found 278.0790.


(*E*)-1-(Allyloxy)-4-fluoro-2-(2-nitrovinyl)benzene (2k)

 Following the general procedure **C**, aldehyde **10k** (1.19 g, 6.59 mmol, 1.0 equiv.) was treated with nitromethane (6.60 mL, 123 mmol, 18.7 equiv.), diisopropylethylamine (113 μL, 0.66 mmol, 0.1 equiv.) and NH₄OAc (1.27 g, 16.5 mmol, 2.5 equiv.). The generated alcohol was treated with Ac₂O (0.69 mL, 7.25 mmol, 1.1 equiv.) in the presence of 4-dimethylaminopyridine (40.3 mg, 0.33 mmol, 0.05 equiv.). The corresponding nitroolefin **2k** was isolated by column chromatography (petane-DCM 8:2) as a yellow solid (366 mg, 1.58 mmol, 24%). **¹H NMR** (300 MHz, CDCl₃): δ = 8.10 (d, *J* = 13.6 Hz, 1H), 7.81 (d, *J* = 13.6 Hz, 1H), 7.21 – 7.06 (m, 2H), 6.96 – 6.86 (m, 1H), 6.07 (ddt, *J* = 17.3, 10.6, 5.4 Hz, 1H), 5.43 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.36 (dq, *J* = 10.5, 1.3 Hz, 1H), 4.64 (dt, *J* = 5.5, 1.5 Hz, 2H); **¹³C NMR** (75 MHz, CDCl₃): δ = 156.8 (d, ¹*J* = 240.7 Hz), 154.7 (d, ⁴*J* = 2.1 Hz), 139.2, 134.2 (d, ⁴*J* = 2.4 Hz), 132.1, 120.4 (d, ³*J* = 7.7 Hz), 119.7 (d, ²*J* = 23.1 Hz), 119.1, 117.6 (d, ²*J* = 23.6 Hz), 113.9 (d, ³*J* = 8.0 Hz), 70.1; **¹⁹F NMR** (282 MHz, Chloroform-*d*): δ = -122.56; **HRMS** (ESI⁺) calculated for C₁₁H₁₀FNO₃+Na⁺ [M+Na]⁺: *m/z* = 246.0537, found 246.0539.

(*E*)-1-(Allyloxy)-4-bromo-2-(2-nitrovinyl)benzene (2l)¹⁰


 Following the general procedure **C**, aldehyde **10l** (1.67 g, 6.91 mmol, 1.0 equiv.) was treated with nitromethane (6.92 mL, 129.18 mmol, 18.7 equiv.), diisopropylethylamine (118 μL, 0.69 mmol, 0.1 equiv.) and NH₄OAc (1.33 g, 17.27 mmol, 2.5 equiv.). The generated alcohol was treated with Ac₂O (0.72 mL, 7.60 mmol, 1.1 equiv.) in the presence of 4-dimethylaminopyridine (42.2 mg, 0.35 mmol, 0.05 equiv.). The corresponding nitroolefin **2l** was isolated by column chromatography (petane-DCM 8:2) as a yellow solid (1.10 g, 3.85 mmol, 56%). **¹H NMR** (300 MHz, CDCl₃): δ = 8.00 (d, *J* = 13.6 Hz, 1H), 7.75 (d, *J* = 13.7 Hz, 1H), 7.50 (d, *J* = 2.5 Hz, 1H), 7.43 (dd, *J* = 8.9, 2.5 Hz, 1H), 6.78 (d, *J* = 8.9 Hz, 1H), 6.00 (ddt, *J* = 17.3, 10.7, 5.4 Hz, 1H), 5.40 – 5.28 (m, 2H), 4.59 (dt, *J* = 5.4, 1.5 Hz, 2H); **¹³C NMR** (75 MHz, CDCl₃): δ = 157.4, 139.2, 135.7, 134.3, 133.9, 131.8, 121.3, 119.3, 114.4, 113.4, 69.9; **HRMS** (ESI⁺) calculated for C₁₁H₁₀BrNO₃+Na⁺ [M+Na]⁺: *m/z* = 305.9736, found 305.9729.

(*E*)-1-(allyloxy)-3,5-dichloro-2-(2-nitrovinyl)benzene (2m)

 Following the general procedure **B**, aldehyde **10m** (749 mg, 3.24 mmol, 1.0 equiv.) was treated with nitromethane (2.1 mL, 39.2 mmol, 12.1 equiv.), acetic acid (0.54 mL,


9.40 mmol, 2.9 equiv.) and NH_4OAc (549 mg, 7.13 mmol, 2.2 equiv.). The corresponding nitroolefin **2m** was isolated by column chromatography (petane-DCM 8:1) as a yellow solid (533 mg, 1.94 mmol, 60%). **^1H NMR** (300 MHz, CDCl_3): δ = 8.42 (d, J = 13.6 Hz, 1H), 8.05 (d, J = 13.6 Hz, 1H), 7.16 (d, J = 1.9 Hz, 1H), 6.89 (d, J = 1.9 Hz, 1H), 6.08 (ddt, J = 17.2, 10.4, 5.5 Hz, 1H), 5.47 (dq, J = 10.0, 1.2 Hz, 1H), 5.42 (dq, J = 3.3, 1.2 Hz, 1H), 4.69 (dt, J = 5.5, 1.4 Hz, 2H); **^{13}C NMR** (75 MHz, CDCl_3): δ = 159.3, 140.9, 138.2, 138.1, 130.6, 130.0, 122.7, 119.9, 116.3, 111.6, 70.6; **HRMS** (ESI^+) calculated for $\text{C}_{11}\text{H}_9\text{Cl}_2\text{NO}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: m/z = 295.9852, found 295.9858.

(E)-N-Allyl-N-(2-(2-nitrovinyl)phenyl)benzamide (2n)




Following the general procedure **A**, aldehyde **10n** (660 mg, 2.48 mmol, 1.0 equiv.) was treated with nitromethane (140 μL , 2.48 mmol, 1.0 equiv.) and 10 M NaOH aq. solution (0.27 mL, 2.73 mmol, 1.1 equiv.) in MeOH (1 mL). The corresponding nitroolefine **2n** was isolated by column chromatography (petane-EtOAc 6:1 \rightarrow 3:1) as a yellow solid (534 mg, 1.73 mmol, 80%). **^1H NMR** (300 MHz, CDCl_3): δ = 8.04 (d, J = 13.6 Hz, 1H), 7.56 – 7.00 (m, 10H), 6.02 (dq, J = 16.5, 7.5 Hz, 1H), 5.23 – 5.09 (m, 2H), 4.64 (dd, J = 14.3, 6.5 Hz, 1H), 4.34 (dd, J = 14.2, 7.0 Hz, 1H); **^{13}C NMR** (75 MHz, CDCl_3): δ = 138.6, 135.3, 134.4, 132.8, 131.9 (2C), 130.3 (2C), 128.5 (2C), 128.5 (2C), 128.4, 128.2, 128.0 (2C), 119.9, 54.0; **HRMS** (ESI^+) calculated for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: m/z = 331.1053, found 331.1054.

(E)-N-Allyl-4-Methyl-N-(2-(2-nitrovinyl)phenyl)benzenesulfonamide (2o)



Following the general procedure **A**, aldehyde **10o** (1.00 g, 3.17 mmol, 1.0 equiv.) was treated with nitromethane (178 μL , 3.33 mmol, 1.05 equiv.) and 10 M NaOH aq. solution (0.35 mL, 3.49 mmol, 1.1 equiv.) in MeOH (0.78 mL). The corresponding nitroolefin **2o** was isolated by column chromatography (petane-DCM-EtOAc 4:1:0.1) as a yellow solid (357 mg, 1.00 mmol, 31%). **^1H NMR** (300 MHz, CDCl_3): δ = 8.21 (d, J = 13.8 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 13.8 Hz, 1H), 7.42 – 7.36 (m, 2H), 7.29 (d, J = 8.1 Hz, 2H), 6.94 – 6.83 (m, 1H), 5.74 (ddt, J = 16.9, 10.0, 6.8 Hz, 1H), 5.13 – 4.85 (m, 2H), 4.44 (br.s, 1H), 3.94 (br.s, 1H), 2.44 (s, 3H); **^{13}C NMR** (75 MHz, CDCl_3): δ = 144.5, 139.7, 138.4, 135.2, 134.9, 132.3, 132.0, 131.8, 130.1, 129.9 (2C), 129.2, 128.2 (2C), 128.0, 120.6, 55.0, 21.7; **HRMS** (ESI^+) calculated for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_4\text{S} + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: m/z = 381.0879, found 381.0878.


(E)-1-(2-Nitrovinyl)-2-(prop-2-yn-1-yloxy)benzene (2p)⁷




Following the general procedure **B**, aldehyde **10p** (1.00 g, 6.24 mmol, 1.0 equiv.) was treated with nitromethane (4.04 mL, 75.5 mmol, 12.1 equiv.), acetic acid (1.03 mL, 18.10 mmol, 2.9 equiv.) and NH_4OAc (1.06 g, 13.73 mmol, 2.2 equiv.). The corresponding nitroolefin **2p** was isolated by column chromatography (petane-DCM 8:2) as a yellow solid (938 mg, 4.62 mmol, 74%). **^1H NMR** (300 MHz, CDCl_3): δ = 8.15 (d, J = 13.6 Hz, 1H), 7.85 (d, J = 13.6 Hz, 1H), 7.54 – 7.40 (m, 2H), 7.16 – 7.00 (m, 2H),

4.84 (d, $J = 2.4$ Hz, 2H), 2.59 (t, $J = 2.4$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 157.3, 138.6, 135.18, 133.4, 132.4, 122.1, 119.7, 112.8, 77.5, 76.8, 56.3$; HRMS (ESI $^+$): calculated for $\text{C}_{11}\text{H}_9\text{NO}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 226.0475$, found 226.0476.


(E)-4-Methyl-2-(2-nitrovinyl)-1-(prop-2-yn-1-yloxy)benzene (2q)

 Following the general procedure **B**, aldehyde **10q** (650 mg, 3.73 mmol, 1.0 equiv.) was treated with nitromethane (2.42 mL, 45.13 mmol, 12.1 equiv.), acetic acid (0.62 mL, 10.82 mmol, 2.9 equiv.) and NH_4OAc (633 mg, 8.21 mmol, 2.2 equiv.). The corresponding nitroolefin **2q** was isolated by column chromatography (petane-DCM 3:1) as a yellow solid (651 mg, 2.99 mmol, 80%). ^1H NMR (300 MHz, CDCl_3): $\delta = 8.13$ (d, $J = 13.7$ Hz, 1H), 7.84 (d, $J = 13.6$ Hz, 1H), 7.34 – 7.18 (m, 2H), 6.99 (d, $J = 8.9$ Hz, 1H), 4.81 (d, $J = 2.4$ Hz, 2H), 2.56 (t, $J = 2.4$ Hz, 1H), 2.32 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 155.4, 138.5, 135.4, 134.0, 132.6, 131.5, 119.5, 112.9, 76.6, 56.4, 20.4$; HRMS (ESI $^+$): calculated for $\text{C}_{12}\text{H}_{11}\text{NO}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 240.0631$, found 240.0639.


(E)-4-Methoxy-2-(2-nitrovinyl)-1-(prop-2-yn-1-yloxy)benzene (2r)

 Following the general procedure **B**, aldehyde **10r** (1.12 g, 5.89 mmol, 1.0 equiv.) was treated with nitromethane (3.82 mL, 71.25 mmol, 12.1 equiv.), acetic acid (0.98 mL, 17.08 mmol, 2.9 equiv.) and NH_4OAc (999 mg, 12.96 mmol, 2.2 equiv.). The corresponding nitroolefin **2r** was isolated by column chromatography (petane-DCM 2:1) as a yellow solid (1.14 g, 4.90 mmol, 83%). ^1H NMR (300 MHz, CDCl_3): $\delta = 8.13$ (d, $J = 13.6$ Hz, 1H), 7.82 (d, $J = 13.6$ Hz, 1H), 7.16 – 6.86 (m, 3H), 4.78 (d, $J = 2.4$ Hz, 2H), 3.81 (s, 3H), 2.56 (t, $J = 2.4$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 154.3, 151.7, 138.8, 135.0, 120.5, 119.0, 116.1, 114.4, 77.9, 76.6, 56.9, 56.0, 20.4$; HRMS (ESI $^+$): calculated for $\text{C}_{12}\text{H}_{11}\text{NO}_4 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 256.0580$, found 256.0580.

(E)-4-Chloro-2-(2-nitrovinyl)-1-(prop-2-yn-1-yloxy)benzene (2s)

 Following the general procedure **A**, aldehyde **10s** (1.18 g, 6.06 mmol, 1.0 equiv.) was treated with nitromethane (341 μL , 6.36 mmol, 1.05 equiv.) and 10 M NaOH aq. solution (666 μL , 6.67 mmol, 1.1 equiv.) in MeOH (1.38 mL). The corresponding nitroolefin **2s** was isolated by column chromatography (petane-DCM 4:1) as a yellow solid (1.08 g, 4.55 mmol, 75%). ^1H NMR (300 MHz, CDCl_3): $\delta = 8.08$ (d, $J = 13.7$ Hz, 1H), 7.81 (d, $J = 13.7$ Hz, 1H), 7.49 – 7.38 (m, 2H), 7.05 (d, $J = 8.8$ Hz, 1H), 4.83 (d, $J = 2.4$ Hz, 2H), 2.59 (t, $J = 2.4$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 155.7, 139.4, 133.6, 132.7, 131.2, 127.1, 121.2, 114.3, 77.2, 77.1, 56.7$; HRMS (ESI $^+$): calculated for $\text{C}_{11}\text{H}_8\text{ClNO}_3 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 260.0085$, found 260.0086.

Optimization of the model organocatalyzed asymmetric reaction^[a]



entry	1	Temp. (°C)	time (d)	yield (%) ^[b]	Ee (%) ^[c]	(Conf.)
1	QN-1a	30	3	99	-90	(<i>S</i>)
2	QD-1b	30	3	99	92	(<i>R</i>)
3	CD-1c	30	3	99	-92	(<i>S</i>)
4	CN-1d	30	3	99	91	(<i>R</i>)
5	QN-1e	30	3	99	-74	(<i>S</i>)
6	1f	30	3	<10	0	0
7	QD-1b	10	4	99	95	(<i>R</i>)
8	QD-1b	10 ^[d]	7	99	96	(<i>R</i>)
9	QD-1b	10 ^{[d],[e]}	7	99	96	(<i>R</i>)

^[a] Catalyst **1** (10 mol %), **2a** (0.1 mmol) and **3** (0.12 mmol) in DCM (0.5 mL, 0.2 M). ^[b] GC-yield. ^[c] Ee determined by chiral HPLC. ^[d] Reaction in *o*-xylene. ^[e] Same results for the reactions in 1 mL *o*-xylene (0.1 M) and 0.2 mL (0.5 M).


An ordinary vial equipped with a magnetic stirring bar was charged with catalyst **1** (10 mol%), malonate **3** (0.24 mmol), nitroolefin **2** (0.20 mmol) and *o*-xylene (1.0 mL) at 10 °C. The stirring was maintained at 10 °C for 7 d. The crude reaction mixture was directly charged onto silica-gel and purified by column chromatography.

The corresponding racemic products were prepared using DABCO (leading to very low yields) or a 1:1 mixture of pseudoenantiomers of the thiourea-chinona derivatives in CH₂Cl₂ at 40 °C for 3 d.


(*R*)-Dimethyl 2-(1-(2-(allyloxy)phenyl)-2-nitroethyl)malonate (**4a**)

According to the general procedure using 10 mol% of catalyst **1b**, the title compound **4a** was obtained after FC (petane-EtOAc 6:1) as a white solid (99%, 96% ee). $[\alpha]_D^{20} = -21.7$ (*c* 1.05 CHCl₃); ¹H NMR (400 MHz, CDCl₃): $\delta = 7.22$ (ddd, *J* = 8.1, 7.5, 1.7 Hz, 1H), 7.15 (dd, *J* = 7.6, 1.7 Hz, 1H), 6.92 – 6.81 (m, 2H), 6.08 (ddt, *J* = 17.3, 10.5, 5.2 Hz, 1H), 5.43 (dq, *J* = 17.3, 1.6 Hz, 1H), 5.32 (dq, *J* = 10.6, 1.4 Hz, 1H), 5.06 (dd, *J* = 13.0, 9.1 Hz, 1H), 4.89 (dd, *J* = 13.0, 4.6 Hz, 1H),

4.65 – 4.54 (m, 2H), 4.42 (td, $J = 9.5, 4.6$ Hz, 1H), 4.21 (d, $J = 9.9$ Hz, 1H), 3.75 (s, 3H), 3.50 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 168.4, 167.7, 156.4, 132.9, 130.8, 129.7, 123.9, 121.1, 118.1, 112.4, 76.1, 69.2, 53.0, 52.7, 52.7, 40.5$; HRMS (ESI $^+$) calculated for $\text{C}_{16}\text{H}_{19}\text{NO}_7 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 360.1054$, found 360.1051. IR: ν_{max} 3027, 2960, 2875, 2360, 2337, 1757, 1723, 1600, 1587, 1552, 1495, 1457, 1433, 1379, 1365, 1348, 1332, 1307, 1288, 1229, 1197, 1170, 1121, 1084, 1067, 1011, 999, 984, 937, 924, 851, 837, 762; HPLC: OD-H, Pentane:*i*-PrOH 90:10, $F = 1.0$ mL/min, $\lambda = 230$ nm, t_{R} minor (*S*) = 10.3 min, t_{R} major (*R*) = 15.1 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	10.607	577.765	59.559	12287.461	49.099
2	17.049	392.306	40.441	12738.391	50.901



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	10.592	0.828	2.622	17.675	1.999
2	16.080	30.742	97.378	866.649	98.001

Optimization and general procedure for the nitrile cycloaddition reaction




Entry	reagent (equiv.)	additive	Solvent	time (h)	Temp.	Yield (%) ^[a]	Ee (%) ^[d]
1	ClCO ₂ Et (2)	Et ₃ N	Benzene	6 h	90 °C	30	Nd
2	PhSO ₂ Cl (2)	Et ₃ N	CHCl ₃	15 h	0 °C à rt	40	Nd
3	PhNCO (1.8)	Et ₃ N	Benzene	4 h	rt à 90 °C	72 ^[b]	Nd
4	Boc ₂ O (2.5)	DMAP	MeCN	3.5 h	60 °C	32	Nd
5	Boc ₂ O (2.5)	DMAP	DCM	3.5 h	60 °C	traces	Nd
6	Boc ₂ O (2.5)	DMAP	Toluene	3.5 h	90 °C	60(75) ^[c]	96 ^[e]
7	Boc ₂ O (2.5)	DMAP	Toluene	24 h	90 °C	40%	Nd
8	Ac ₂ O (2.5)	DMAP	Toluene	3.5 h	90 °C	57%	Nd

^[a] Isolated yields. ^[b] **5a** together with inseparable byproducts. ^[c] NMR yield in brackets. ^[d] Ee determined by HPLC.


^[e] Starting from **4a** with 96% ee. N.d. = not determined.

General Procedure with Boc₂O and DMAP:



Nitro compound **4** (0.2 mmol, 1.0 equiv.) and DMAP (0.04 mmol, 0.2 equiv.) were dissolved in freshly distilled toluene and heated to 90 °C. To the hot reaction mixture, a solution of Boc₂O in toluene (0.5 M, 1.0 mL, 2.5 equiv.) was added over 20 min. The reaction was then allowed to proceed for further 3.5 h at 90 °C. After cooling to room temperature, the crude reaction mixture was directly charged onto silica-gel and purified by column chromatography.


General procedure for the one-pot reaction




A schlenk tube was charged with catalyst **1** (10 mol%), malonate or diketone **3** (0.24 mmol), nitroolefin **2** (0.20 mmol) and dry *o*-xylene (1.0 mL) at 10 °C. The stirring was maintained at 10 °C for 7 d. Then, 0.1 mL of

a solution of 4-DMAP (4.9 mg, 0.04 mmol, 0.2 equiv.) and Boc₂O (109.1 mg, 0.5 mmol, 2.5 equiv.) in dry *o*-xylene (1.0 mL) was added at room temperature and the mixture stirred for 5 min. The reaction mixture was then heated at 90 °C and the rest of the solution (0.9 mL) added dropwise. (Alternatively, the reaction mixture was added dropwise to a mixture of DMAP and Boc₂O in *o*-xylene heated at 90 °C). The reaction was then allowed to proceed for further 3.5 h at 90 °C. After cooling to room temperature the crude reaction mixture was directly charged onto silica-gel and purified by column chromatography.


Dimethyl 2-((3a*R*,10*R*)-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5a)




Following the general procedure, the title compound **5a** was obtained after FC (petane-EtOAc 8:1) as a white solid (61%) and a 3:1 mixture of diastereoisomers (96% ee each). ¹H NMR (300 MHz, CDCl₃): δ = 7.36 – 6.94 (m, 4H major + 4H minor), 4.88 (d, *J* = 11.8 Hz, 1H major), 4.67 (d, *J* = 11.8 Hz, 1H minor), 4.56 – 4.41 (m, 2H major + 2H minor), 4.40 – 4.28 (m, 1H major + 1H minor), 3.79 (s, 3H major), 3.76 (s, 3H minor), 3.62 (s, 3H major), 3.50 (s, 3H minor) 3.92-3.50 (m, 3H major + 2H minor); ¹³C NMR (75 MHz, CDCl₃): Major isomer: δ = 168.1, 167.8, 158.1, 132.0, 130.1, 129.6, 126.8, 125.5, 122.7, 74.1, 70.5, 53.3, 53.1, 53.1, 51.6, 39.5; Minor isomer: δ = 167.4, 167.2, 156.7, 131.9, 131.2, 130.0, 128.8, 125.2, 122.8, 74.5, 70.4, 53.8, 53.2, 52.7, 50.2, 44.0; HRMS (ESI⁺) calculated for C₁₆H₁₇NO₆+Na⁺ [M+Na]⁺: *m/z* = 342.0948, found 342.0950; IR: ν_{max} 3075, 2957, 2889, 2360, 1738, 1718, 1635, 1603, 1579, 1488, 1453, 1438, 1431, 1352, 1325, 1312, 1294, 1282, 1267, 1240, 1223, 1199, 1178, 1148, 1008, 890, 875, 788, 774; HPLC: IC, Pentane:*i*-PrOH 65:35, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t*_R minor = 20.3 min, *t*_R major = 54.7 min; Minor isomer: *t*_R major = 16.7 min, *t*_R minor = 25.0 min.



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	18.320	29.879	27.203	1051.312	16.893
2	22.023	43.883	39.953	1864.406	29.958
3	27.730	19.500	17.754	1131.214	18.177
4	61.716	16.573	15.089	2176.367	34.971




Dimethyl 2-((3a*S*,10*S*)-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (*ent*-5a)




Following the general procedure, the title compound *ent*-5a was obtained after FC (petane-EtOAc 8:1) as a white solid (75%) and a 2.8:1 mixture of diastereoisomers (97% ee each).


¹H NMR (400 MHz, CDCl₃): δ = 7.32 (dd, *J* = 7.6, 1.7 Hz, 1H, minor), 7.30 – 7.19 (m, 2H major + 2H minor), 7.19 (dd, *J* = 7.8, 2.1 Hz, 1H, major), 7.12 (dd, *J* = 7.5, 1.4 Hz, 1H, major), 7.12 – 7.03 (m, 1H major + 1H minor), 7.01 (dd, *J* = 8.0, 1.3 Hz, 1H, minor), 4.89 (d, *J* = 11.8 Hz, 1H, major), 4.68 (d, *J* = 11.8 Hz, 1H, minor), 4.56 – 4.43 (m, 2H major + 2H minor), 4.40 – 4.29 (m, 1H major + 1H minor), 3.95 – 3.79 (m, 2H major + 2H minor), 3.80 (s, 3H major), 3.77 (s, 3H minor), 3.72 – 3.65 (m, 1H major), 3.63 (s, 3H), 3.58 – 3.53 (m, 1H minor), 3.51 (s, 3H minor); **¹³C NMR** (100 MHz, CDCl₃): Major isomer: δ = 168.1, 167.8, 158.2, 132.1, 130.1, 129.6, 126.8, 125.6, 122.8, 74.1, 70.5, 53.3, 53.1, 53.1, 51.6, 39.5; Minor isomer: δ = 167.5, 167.2, 159.3, 156.7, 132.1, 130.1, 128.8, 125.2, 122.8, 74.5, 70.4, 53.8, 53.2, 52.7, 50.2, 44.0; **HRMS** (ESI⁺) calculated for C₁₆H₁₇NO₆+Na⁺ [M+Na]⁺: *m/z* = 342.0948, found 342.0951; **IR**: ν_{max} 3075, 2957, 2889, 2360, 1738, 1718, 1635, 1603, 1579, 1488, 1453, 1438, 1431, 1352, 1325, 1312, 1294, 1282, 1267, 1240, 1223, 1199, 1178, 1148, 1008, 890, 875, 788, 774; **HPLC**: IC, Pentane:*i*-PrOH 65:35, F = 1.0 mL/min, λ = 230 nm: Major isomer: t_R major = 20.0 min, t_R minor = 54.3 min; Minor isomer: t_R minor = 16.8 min, t_R major = 24.6 min.




Diethyl 2-((3a*R*,10*R*)-3a-methyl-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5b)



Following the general procedure, the title compound **5b** was obtained after FC (petane-EtOAc 8:1) as a white solid (69%) and a 2.5:1 mixture of diastereoisomers (96% ee each). **¹H NMR** (400 MHz, CDCl₃): δ = 7.32 (dd, *J* = 7.6, 1.7 Hz, 1H minor), 7.26 – 7.18 (m, 2H major + 1H minor), 7.13 – 6.96 (m, 2H major + 2H minor), 4.88 (d, *J* = 11.9 Hz, 1H major), 4.66 (d, *J* = 11.8 Hz, 1H minor), 4.55 – 4.40 (m, 2H major + 2H minor), 4.37 – 4.29 (m, 1H major + 1H minor), 4.29 – 4.16 (m, 2H major + 1H minor), 4.08 (q, *J* = 7.1 Hz, 2H major), 4.00 – 3.77 (m, 2H major + 3 H minor), 3.65 (t, *J* = 11.0 Hz, 1H major), 3.53 (t, *J* = 11.6 Hz, 1H minor), 1.27 (td, *J* = 7.1, 6.4 Hz, 3H major + 3H minor), 1.11 (t, *J* = 7.1 Hz, 3H major), 1.02 (t, *J* = 7.1 Hz, 3H minor); **¹³C NMR** (100 MHz, CDCl₃): Major isomer: δ = 167.6, 167.4, 158.2, 158.1, 130.2, 129.5, 126.8, 125.4, 122.6, 74.1, 70.4, 62.2, 62.0, 53.4, 51.8, 39.3, 14.1, 14.0; Minor isomer: δ = 167.1, 166.7, 159.3, 156.7, 132.1, 129.9, 129.0, 125.1, 122.7, 74.6, 70.3, 62.2, 61.6, 53.9, 50.2, 44.0, 14.1, 13.9; **HRMS** (ESI⁺) calculated for C₁₈H₂₁NO₆+Na⁺ [M+Na]⁺: *m/z* = 370.1261, found 370.1263; **IR**: ν_{max} 3065, 2982, 2895, 1739, 1717, 1602, 1489, 1447, 1374, 1344, 1276, 1267, 1217, 1192, 1145, 1105, 1059, 1040, 1015, 1000, 948, 916, 885, 857, 826, 786, 775, 625; **HPLC**: IC, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t_R* major = 107.3 min, *t_R* minor = 39.3 min; Minor isomer: *t_R* minor = 63.0 min, *t_R* major = 28.5 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	28.312	48.170	33.308	2623.927	20.242
2	38.864	56.957	39.304	4213.660	32.505
3	62.118	25.213	17.434	2955.840	22.802
4	106.752	14.281	9.875	3169.610	24.451





#	Meas. Ret. Time	Height	Height %	Area	Area %
1	28.457	43.908	56.707	2531.797	26.756
2	39.313	1.539	1.988	132.692	1.402
3	63.006	0.510	0.658	81.709	0.864
4	107.293	31.473	40.647	6716.169	70.978

Diisopropyl 2-((3a*R*,10*R*)-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (**5c**)




Following the general procedure, the title compound **5c** was obtained after FC (petane-EtOAc 8:1) as a white solid (75%) and a 2.2:1 mixture of diastereoisomers (90% ee each). ¹H NMR (400 MHz, CDCl₃): δ = 7.33 (dd, *J* = 7.6, 1.7 Hz, 1H minor), 7.25 – 7.17 (m, 2H major + 1H minor), 7.10 – 7.02 (m, 2H major), 7.00 (dd, *J* = 8.0, 1.3 Hz, 1H minor), 5.07 (hept, *J* = 6.3 Hz, 1H major), 5.07 (hept, *J* = 6.3 Hz, 1H minor), 4.94 (hept, *J* = 6.3 Hz, 1H major), 4.87 (d, *J* = 12.0 Hz, 1H major), 4.81 (hept, *J* = 6.3 Hz, 1H minor), 4.64 (d, *J* = 11.9 Hz, 1H minor), 4.52 (ddd, *J* = 11.8, 6.7, 5.1 Hz, 1H major + 1H minor), 4.43 (d, *J* = 12.0 Hz, 1H major), 4.43 (dd, *J* = 10.9, 8.4 Hz, 1H minor), 4.34 (dd, *J* = 10.3, 8.1 Hz, 1H major), 4.27 (d, *J* = 11.9 Hz, 1H minor), 4.21 (tdd, *J* = 11.3, 8.4, 6.4 Hz, 1H minor), 3.96 – 3.85 (m, 1H major + 1H minor), 3.81 (t, *J* = 8.1 Hz, 1H major), 3.61 (t, *J* = 11.2 Hz, 1H major), 3.53 (t, *J* = 11.6 Hz, 1H minor),


1.28 (d, $J = 6.3$ Hz, 3H major), 1.26 (d, $J = 3.1$ Hz, 3H minor), 1.24 (d, $J = 6.1$ Hz, 3H major), 1.24 (d, $J = 3.1$ Hz, 3H minor), 1.14 (d, $J = 6.3$ Hz, 3H major), 1.10 (d, $J = 6.4$ Hz, 3H major) 1.15 – 1.10 (m, 3H minor), 0.93 (d, $J = 6.3$ Hz, 3H minor); ^{13}C NMR (100 MHz, CDCl_3): Major isomer: $\delta = 167.1, 167.0, 158.4, 158.1, 130.3, 129.3, 126.6, 125.3, 122.5, 74.2, 70.2, 69.7, 69.5, 53.5, 52.0, 39.0, 21.7, 21.6, 21.5, 21.4$; Minor isomer: $\delta = 166.7, 166.3, 159.4, 156.8, 132.3, 129.9, 129.1, 125.0, 122.7, 74.6, 70.3, 69.9, 69.2, 54.2, 50.2, 43.8, 21.7$ (2C), 21.5, 21.4; **HRMS** (ESI^+) calculated for $\text{C}_{20}\text{H}_{25}\text{NO}_6 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 398.1574$, found 398.1579; **IR**: ν_{max} 3065, 2982, 2936, 2881, 2363, 2342, 1744, 1729, 1488, 1466, 1454, 1375, 1297, 1260, 1239, 1219, 1177, 1164, 1097, 1006, 8914, 824, 785, 773; **HPLC**: AS-H, Pentane:*i*-PrOH 95:05, $F = 1.0$ mL/min, $\lambda = 230$ nm: Major isomer: t_{R} major = 20.2 min, t_{R} minor = 14.5 min; Minor isomer: t_{R} minor = 26.7 min, t_{R} major = 15.7 min.




3-((3*aR*,10*R*)-3,3*a*,4,10-Tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)pentane-2,4-dione (5d)




Following the general procedure, the title compound **5d** was obtained after FC (petane-EtOAc 6:1) as a white solid (46%) and a 5.0:1 mixture of diastereoisomers (90% ee each). ¹H NMR (400 MHz, CDCl₃): δ 7.27 – 7.20 (m, 2H major + 2H minor), 7.11 – 7.05 (m, 1H major + 2H minor), 7.02 (dd, *J* = 7.9, 1.3 Hz, 1H major), 5.00 (d, *J* = 12.1 Hz, 1H minor), 4.93 (d, *J* = 12.1 Hz, 1H minor), 4.76 (d, *J* = 11.9 Hz, 1H major), 4.65 (d, *J* = 11. Hz, 1H major), 4.56 (dd, *J* = 11.3, 7.1 Hz, 1H minor), 4.52 (dd, *J* = 11.5, 6.3 Hz, 1H major), 4.43 (dd, *J* = 11.0, 8.4 Hz, 1H major), 4.36 (dd, *J* = 10.4, 8.2 Hz, 1H minor), 4.02 (tdd, *J* = 11.3, 8.9, 6.3 Hz, 1H major), 3.95 – 3.89 (m, 1H minor), 3.86 (t, *J* = 8.7 Hz, 1H major), 3.80 (t, *J* = 8.4 Hz, 1H minor), 3.58 (t, *J* = 11.3 Hz, 1H minor), 3.54 (t, *J* = 11.6 Hz, 1H major), 2.39 (s, 3H minor), 2.26 (s, 3H major), 2.02 (s, 3H minor), 1.86 (s, 3H major); ¹³C NMR (100 MHz, CDCl₃): Major isomer: δ = 202.5, 202.2, 159.1, 156.5, 132.0, 130.0, 128.6, 125.5, 123.0, 74.5, 70.8, 70.4, 50.0, 44.1, 32.1, 26.8; Minor isomer: δ = 202.4, 202.3, 159.1, 156.5, 132.0, 129.7, 126.7, 125.9, 122.8, 74.4, 70.5, 69.5, 52.1, 39.0, 30.8, 29.8; **HRMS** (ESI⁺) calculated for C₁₆H₁₇NO₄+Na⁺ [M+Na]⁺: *m/z* = 310.1050, found 310.1058; **IR**: ν_{max} 3002, 2969, 2928, 2878, 2361, 2342, 1715, 1691, 1487, 1449, 1411, 1358, 1292, 1268, 1224, 1199, 1187, 1154, 1103, 1011, 922, 866, 843, 774, 621, 612; **HPLC**: OD-H, Pentane:*i*-PrOH 90:10, *F* = 1.0 mL/min, λ = 230 nm: Major isomer: *t_R* major = 17.8 min, *t_R* minor = 13.6 min; Minor isomer: *t_R* minor = 24.8 min, *t_R* major = 15.5 min.



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	13.654	194.960	51.807	5268.562	43.472
2	15.724	28.457	7.562	944.606	7.794
3	18.144	132.879	35.310	4881.713	40.280
4	25.069	20.022	5.321	1024.559	8.454




Dimethyl 2-((3a*R*,10*R*)-8-methyl-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5e)




Following the general procedure, the title compound **5e** was obtained after FC (petane-EtOAc 8:1) as a white solid (72%) and a 2.7:1 mixture of diastereoisomers (95% ee each).

¹H NMR (300 MHz, CDCl₃): δ = 7.13 – 6.85 (m, 3H major + 3H minor), 4.84 (d, *J* = 11.8 Hz, 1H major), 4.60 (d, *J* = 11.8 Hz, 1H minor), 4.55 – 4.24 (m, 3H major + 3 minor), 4.17 (qd, *J* = 11.2, 7.1 Hz, 1H minor), 3.95 – 3.72 (m, 6H major + 2H minor), 3.63 (s, 3H major + 3H minor), 3.51 (s, 3H minor), 2.28 (s, 3H major + 3H minor); **¹³C NMR** (75 MHz, CDCl₃): Major isomer: δ = 168.1, 167.8, 158.3, 155.8, 135.1, 129.9, 129.6, 127.3, 122.3, 74.1, 70.5, 53.3, 53.1, 53.0, 51.6, 39.4, 21.1; Minor isomer: δ = 167.5, 167.2, 157.1, 156.8, 134.8, 132.3, 130.4, 128.3, 122.4, 74.7, 70.4, 53.8, 53.2, 52.6, 50.2, 44.0, 20.8; **HRMS** (ESI⁺) calculated for C₁₇H₁₉NO₆+Na⁺ [M+Na]⁺: *m/z* = 356.1105, found 356.1104; **IR**: ν_{max} 2978, 2957, 2920, 2904, 2360, 2337, 1746, 1722, 1496, 1452, 1428, 1299, 1261, 1240, 1200, 1156, 1004, 975, 915, 887, 831, 801; **HPLC**: AD-H, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t_R* major = 26.2 min, *t_R* minor = 57.0 min; Minor isomer: *t_R* minor = 21.4 min, *t_R* major = 23.9 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	21.375	47.351	18.427	1476.363	11.971
2	23.885	35.850	13.951	1279.091	10.372
3	26.166	116.841	45.469	4494.651	36.445
4	56.613	56.928	22.154	5082.489	41.212



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	21.421	2.131	0.769	70.461	0.678
2	23.946	88.943	32.104	3142.225	30.229
3	26.242	183.765	66.329	6973.131	67.083
4	57.046	2.212	0.798	208.962	2.010


Dimethyl 2-((3a*R*,10*R*)-8-methoxy-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5f)




Following the general procedure, the title compound **5f** was obtained after FC (petane-EtOAc 5:1) as a white solid (63%) and a 3:1 mixture of diastereoisomers (95% ee each).

¹H NMR (300 MHz, CDCl₃): δ = 7.02 – 6.95 (m, 1H major), 6.92 (d, *J* = 8.7 Hz, 1H minor), 6.83 (d, *J* = 3.0 Hz, 1H minor), 6.76 – 6.69 (m, 2H major + 1H minor), 4.85 (d, *J* = 11.8 Hz, 1H major), 4.60 (d, *J* = 11.8 Hz, 1H minor), 4.54 – 4.28 (m, 3H major + 3H minor), 3.94 – 3.77 (m, 2H major + 2H minor), 3.78 (s, 3H major), 3.76 (s, 3H minor), 3.75 (s, 3H minor), 3.74 (s, 3H major), 3.66 (s, 3H major), 3.60 (t, *J* = 10.9 Hz, 1H major), 3.54 (s, 3H minor), 3.49 (t, *J* = 11.6 Hz, 1H minor); ¹³C NMR (75 MHz, CDCl₃): Major isomer: δ = 168.0, 167.8, 158.1, 156.8, 151.8, 130.8, 123.3, 114.0, 112.1, 74.5, 70.5, 55.7,

53.3, 53.2, 53.0, 51.7, 39.5; Minor isomer: δ = 167.4, 167.1, 156.7, 156.4, 152.9, 129.5, 123.5, 116.4, 115.2, 74.9, 70.4, 55.8, 53.7, 53.2, 52.7, 50.1, 44.1; **HRMS** (ESI⁺) calculated for C₁₇H₁₉NO₇+Na⁺ [M+Na]⁺: m/z = 372.1054, found 372.1061; **IR**: ν_{\max} 3008, 2956, 2923, 2848, 2361, 1755; 1735, 1610, 1580, 1495, 1433, 1284, 1261, 1238, 1197, 1149, 1034, 1009, 993, 887, 831; **HPLC**: IC, Pentane:*i*-PrOH 65:35, F = 1.0 mL/min, λ = 230 nm: Major isomer: t_R minor = 23.9 min, t_R major = 90.9 min; Minor Isomer: t_R minor = 22.2 min, t_R major = 28.8 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	22.233	68.535	32.747	3216.556	21.494
2	23.859	76.053	36.339	5055.543	33.783
3	29.080	46.317	22.131	2864.073	19.139
4	92.385	18.382	8.783	3828.540	25.584




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	22.249	3.899	1.580	166.418	0.643
2	23.938	7.340	2.974	410.448	1.586
3	28.779	159.288	64.534	9530.808	36.827
4	90.947	76.303	30.913	15772.138	60.944

Dimethyl 2-((3a*R*,10*R*)-7-methoxy-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5g)




Following the general procedure, the title compound **5g** was obtained after FC (petane-EtOAc 4:1) as a white solid (52%) and a 3:1 mixture of diastereoisomers (95% ee each).


¹H NMR (400 MHz, CDCl₃): δ 7.20 (d, *J* = 8.5 Hz, 1H), 7.11 – 7.05 (m, 1H major), 6.66 – 6.58 (m, 2H major + 1H minor), 6.55 (d, *J* = 2.6 Hz, 1H minor), 4.77 (d, *J* = 11.6 Hz, 1H major), 4.61 (d, *J* = 11.8 Hz, 1H minor), 4.54 – 4.38 (m, 2H major + 2H minor), 4.35 – 4.25 (m, 1H major + 1H minor), 4.21 – 4.14 (m, 1H minor), 3.91 – 3.65 (m, 10H major + 8H minor), 3.61 (s, 3H major), 3.52 (s, 1H minor); **¹³C NMR** (100 MHz, CDCl₃): Major isomer : δ = 168.1, 167.8, 160.5, 158.8, 158.4, 127.7, 121.9, 110.6, 108.9, 73.9, 70.5, 55.5, 53.4, 53.2, 53.0, 51.4, 39.1; Minor isomer: δ = 167.5, 167.2, 160.8, 160.2, 156.8, 132.6, 120.6, 110.6, 108.3, 74.6, 70.3, 55.5, 54.0, 53.1, 52.6, 50.2, 43.3; (ESI+) calculated for C₁₇H₁₉NO₇+Na⁺ [M+Na]⁺: *m/z* = 372.1054, found 372.1047; **IR**: ν_{max} 3006, 2978, 2959, 2923, 2837, 2360, 2325, 1744, 1722, 1611, 1574, 1500, 1450, 1438, 1374, 1350, 1311, 1295, 1281, 1259, 1196, 1178, 1149, 1126, 1106, 1085, 1034, 1018, 976, 936, 914, 884, 851, 835, 824, 794; **HPLC**: IC, Pentane:*i*-PrOH 65:35, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t_R* major = 77.6 min, *t_R* minor = 30.3 min; Minor isomer: *t_R* minor = 37.9 min, *t_R* major = 22.8 min.



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	23.011	7.098	21.058	394.240	13.080
2	30.354	16.526	49.030	1218.567	40.429
3	38.135	5.195	15.414	530.667	17.606
4	78.846	4.887	14.499	870.610	28.885




Dimethyl 2-((3a*R*,10*R*)-6-methoxy-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5h)




Following the general procedure, the title compound **5h** was obtained after FC (petane-EtOAc 8:1) as a white solid (87%) and a 20:1 mixture of diastereoisomers (95% ee each).

Only signals of the major diastereoisomer: **¹H NMR** (400 MHz, CDCl₃): δ = 7.05 (t, *J* = 8.1 Hz, 1H), 6.87 (dd, *J* = 8.4, 1.4 Hz, 1H), 6.76 (ddd, *J* = 7.9, 1.3, 0.6 Hz, 1H), 4.92 (d, *J* = 11.9

Hz, 1H), 4.57 (dd, *J* = 11.0, 7.2 Hz, 1H), 4.51 (d, *J* = 11.9 Hz, 1H), 4.37 – 4.31 (m, 1H), 3.88 – 3.81 (m, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.63 (s, 3H); **¹³C NMR** (101 MHz, CDCl₃): δ = 168.1, 167.8, 158.0, 152.6, 131.6, 125.7, 125.7, 118.0, 112.1, 73.6, 70.5, 56.1, 53.3, 53.1, 53.1, 51.8, 39.4; **HRMS** (ESI⁺) calculated for C₁₇H₁₉NO₇+Na⁺ [M+Na]⁺: *m/z* = 372.1054, found 372.1056; **IR**: ν_{max} 3001, 2955, 2886, 2841, 2360, 2333, 1736, 1599, 1584, 1481, 1456, 1436, 1370, 1275, 1259, 1241, 1199, 1148, 1088, 1059, 1004, 915, 884, 753, 729; **HPLC**: OD-H, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t_R* major = 45.9 min, *t_R* minor = 57.5 min; Minor isomer: *t_R* minor = 23.1min, *t_R* major = 26.0 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	22.125	42.467	29.758	3148.434	18.425
2	25.468	32.434	22.727	2864.733	16.765
3	46.289	41.879	29.346	5102.828	29.863
4	52.216	25.928	18.169	5971.644	34.947




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	23.054	0.269	0.160	22.191	0.097
2	26.012	11.596	6.873	1057.268	4.637
3	45.919	155.007	91.870	21139.598	92.722
4	57.537	1.851	1.097	579.850	2.543

Dimethyl 2-((3a*R*,10*R*)-7-(diethylamino)-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5i)




Following the general procedure, the title compound **5i** was obtained after FC (petane-EtOAc 5:1) as a white solid (66%) and a 2.5:1 mixture of diastereoisomers (95% ee each). ¹H NMR (300 MHz, CDCl₃): δ = 7.09 (d, *J* = 8.5 Hz, 1H minor), 6.97 (d, *J* = 8.4 Hz, 1H major), 6.45 – 6.23 (m, 2H major + minor), 4.73 (d, *J* = 11.8 Hz, 1H major), 4.56 (d, *J* = 11.7 Hz, 1H minor), 4.51 – 4.38 (m, 2H major + 2 H minor), 4.37 – 4.24 (m, 1H major + 1H minor), 3.78 (s, 3H major), 3.74 (s, 1H minor), 3.64 (s, 3H major), 3.55 (s, 3H minor), 3.89 – 3.52 (m, 3H major + 3H minor), 3.30 (q, *J* = 7.1 Hz, 4H major + 4H minor), 1.13 (t, *J* = 7.1 Hz, 6H major + 6H minor); ¹³C NMR (75 MHz, CDCl₃): Major isomer: δ = 168.3, 168.0, 159.1, 159.0, 149.0, 127.5, 115.5, 108.1, 105.4,

74.0, 70.4, 53.5, 53.2, 53.0, 51.7, 44.4 (2C), 38.9, 12.6 (2C); Minor isomer: δ = 167.7, 167.4, 160.4, 157.4, 149.3, 132.6, 114.0, 108.0, 105.0, 74.5, 70.2, 54.4, 53.1, 52.6, 50.3, 44.4 (2C), 43.2, 12.6 (2C); **HRMS** (ESI⁺) calculated for C₂₀H₂₆N₂O₆+Na⁺ [M+Na]⁺: m/z = 413.1683, found 413.1681; **IR**: ν_{\max} 2969, 2933, 2882, 1756, 1736, 1614, 1557, 1512, 1434, 1398, 1376, 1297, 1272, 1257, 1238, 1216, 1193, 1146, 1108, 1080, 1021, 916, 882, 729; **HPLC**: IA, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: Major isomer: t_R minor = 26.3 min, t_R major = 31.8 min; Minor isomer: t_R major = 17.9 min, t_R minor = 22.4 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	17.979	32.074	16.656	1005.206	12.424
2	22.297	38.321	19.900	1362.953	16.846
3	25.902	71.618	37.190	3287.861	40.637
4	31.916	50.558	26.254	2434.723	30.093



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	17.877	157.791	38.721	4692.175	28.028
2	22.403	3.458	0.849	143.628	0.858
3	26.266	6.840	1.678	321.446	1.920
4	31.786	239.418	58.752	11584.077	69.195

Dimethyl 2-((8a*R*,12*R*)-8,8a,9,12-tetrahydronaphtho[1',2':6,7]oxepino[4,3-*c*]isoxazol-12-yl)malonate (5j**)**




Following the general procedure, the title compound **5j** was obtained after FC (pentane-EtOAc 5:1) as a white solid (63%) and a 3.8:1 mixture of diastereoisomers (81% ee each).

¹H NMR (300 MHz, CDCl₃): δ = 8.36 (d, *J* = 8.7 Hz, 1H minor), 8.28 (d, *J* = 8.7 Hz, 2H major), 7.90 – 7.72 (m, 2H major + 2H minor), 7.66 – 7.53 (m, 1H major + 1H minor), 7.53


– 7.39 (m, 1H major + 1H minor), 7.26 (d, *J* = 8.7 Hz, 1H major), 7.20 (d, *J* = 8.8 Hz, 1H minor), 5.65 (d, *J* = 11.8 Hz, 1H minor), 5.63 (d, *J* = 9.8 Hz, 1H major), 4.76 (d, *J* = 11.7 Hz, 1H minor), 4.64 (dd, *J* = 11.3, 6.7 Hz, 1H minor), 4.54 (d, *J* = 9.8 Hz, 1H major), 4.49 (dd, *J* = 11.0, 8.3 Hz, 1H minor), 4.36 – 4.15 (m, 3H major + 1H minor), 4.08 (dd, *J* = 8.5, 6.3 Hz, 1H major), 3.86 (s, 3H major), 3.83 (s, 3H minor), 3.89 – 3.76 (m, 1H major) 3.66 – 3.55 (m, 2H minor), 3.45 – 3.29 (m, 1H major), 3.20 (s, 3H minor), 3.09 (s, 3H major);

¹³C NMR (75 MHz, CDCl₃): Major isomer: δ = 168.4, 167.2, 159.7, 153.4, 131.9, 131.7, 131.1, 128.6, 127.0, 125.3, 125.0, 123.9, 122.1, 71.9, 71.3, 55.6, 53.1, 52.2, 48.5, 35.6; Minor isomer: δ = 167.7, 167.0, 157.9, 156.4, 131.8, 131.6, 130.9, 130.8, 128.5, 125.0, 124.3, 123.6, 122.3, 74.8, 70.3, 53.3, 53.2, 52.4, 49.9, 36.7;


HRMS (ESI⁺) calculated for C₂₀H₁₉NO₆+Na⁺ [*M*+Na]⁺: *m/z* = 392.1105, found 392.1109; **IR**: ν_{max} 3059, 2953, 2884, 2361, 1735, 1622, 1594, 1512, 1434, 1376, 1332, 1297, 1242, 1219, 1150, 1079, 1008, 913, 885, 859, 830, 753, 730; **HPLC**: IC, Pentane:*i*-PrOH 75:25, *F* = 1.2 mL/min, λ = 230 nm: Major isomer: *t_R* minor = 31.6 min, *t_R* major = 194.6 min; Minor isomer: *t_R* minor = 17.4 min, *t_R* major = 27.5 min.



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	18.186	42.744	22.319	1937.726	9.349
2	29.878	21.545	11.250	1838.441	8.870
3	33.759	110.052	57.464	8273.394	39.916
4	220.607	17.175	8.968	8677.504	41.866





Dimethyl 2-((3a*R*,10*R*)-8-fluoro-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5k**)**




Following the general procedure, the title compound **5k** was obtained after FC (petane-EtOAc 5:1) as a white solid (57%) and a 2.8:1 mixture of diastereoisomers (96% ee each).

¹H NMR (300 MHz, CDCl₃): δ = 7.10 – 6.86 (m, 3H major + 3H minor), 4.87 (d, J = 11.7 Hz, 1H major), 4.62 (d, J = 11.8 Hz, 1H minor), 4.56 – 4.41 (m, 2H major + 2H minor), 4.41 – 4.30 (m, 1H major+ 1H minor), 3.96 – 3.80 (m, 2H major + 2H minor), 3.79 (s, 3H major), 3.77 (s, 3H minor), 3.69 (s, 3H major), 3.66 – 3.47 (m, 1H major + 1 H minor); 3.57 (s, 3H minor); **¹³C NMR** (75 MHz, CDCl₃): Major isomer: δ = 167.8, 167.6, 159.7 (d, 1J = 244.5 Hz), 157.6, 154.2 (d, 4J = 2.9 Hz), 132.0 (d, 3J = 7.9 Hz), 124.0 (d, 3J = 8.7 Hz), 115.8 (d, 2J = 22.7 Hz), 113.7 (d, 3J = 25.0 Hz), 74.4 (d, 6J = 1.5 Hz), 70.6, 53.4, 53.3, 52.8, 51.6, 39.3 (d, 4J = 1.3 Hz); Minor Isomer: δ = 167.2, 167.0, 159.1 (d, 1J = 244.6 Hz), 156.2; 155.3 (d, 4J = 2.8 Hz), 130.6 (d, 3J = 8.0 Hz), 124.2 (d, 3J = 8.5 Hz), 118.5 (d, 2J = 24.0 Hz), 116.5 (d, 2J = 22.8 Hz), 74.8 (d, 6J = 0.9 Hz), 70.5, 53.6, 53.3, 52.8, 50.1, 43.7 (d, 4J = 1.4 Hz); **HRMS** (ESI⁺) calculated for C₁₆H₁₆FNO₆+Na⁺ [M+Na]⁺: m/z = 360.0854, found 360.0844; **¹⁹F NMR** (282 MHz, CDCl₃): δ = -115.99 (major), -117.14 (minor); **IR**: ν_{\max} 3078, 3007, 2958, 2923, 2852, 1754, 1736, 1590, 1489, 1430, 1383, 1350, 1305, 1262, 1239, 1184, 1145, 1014, 1005, 978, 962, 918, 887, 870, 842, 823; **HPLC**: IC, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 210 nm: Major isomer: t_R minor = 27.4 min, t_R major = 63.4 min; Minor isomer: t_R major = 19.5 min, t_R minor = 35.5 min.




Dimethyl 2-((3a*R*,10*R*)-8-bromo-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5I**)**




Following the general procedure, the title compound **5I** was obtained after FC (petane-EtOAc 5:1) as a white solid (50%) and a 3.6:1 mixture of diastereoisomers (92% ee each).

¹H NMR (300 MHz, CDCl₃): δ = 7.47 (d, *J* = 2.4 Hz, 1H, minor), 7.40 – 7.31 (m, 2H, major + 2H, minor), 6.96 (d, *J* = 8.4 Hz, 1H, major), 6.90 (d, *J* = 8.5 Hz, 1H, minor), 4.84 (d, *J* = 11.6 Hz, 1H, major), 4.61 (d, *J* = 11.7 Hz, 1H, minor), 4.56 – 4.15 (m, 4H, major + 1 H, minor), 3.96 – 3.81 (m, 2H, major + 2 H minor), 3.79 (s, 3H, major), 3.77 (s, 1H, minor), 3.70 (s, 3H, major), 3.65 (t, *J* = 9.0 Hz, 1H, major), 3.57 (s, 1H, minor), 3.56 – 3.43 (m, 2H, minor). **¹³C NMR** (150 MHz, CDCl₃): Major isomer: δ = 167.8, 167.6, 157.5, 157.2, 132.5, 132.4, 130.1, 124.5, 118.2, 74.1, 70.6, 53.3, 53.2, 52.9, 51.4, 39.4; Minor isomer: δ = 167.2, 166.9, 158.4, 156.1, 134.6, 132.9, 131.0, 124.7, 117.7, 74.6, 70.4, 53.7, 53.3, 52.8,

50.0, 43.6; **HRMS** (ESI⁺) calculated for C₁₆H₁₆BrNO₆+Na⁺ [M+Na]⁺: m/z = 420.0053, found 420.0056; **IR**: ν_{max} 2915, 2872, 1682, 1591, 1475, 1412, 1392, 1271, 1236, 1222, 1180, 1124, 1098, 1013, 993, 936, 901, 885, 876, 852, 810; **HPLC**: IA, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: Major isomer: t_R major = 22.0 min, t_R minor = 55.6 min; Minor isomer: t_R minor = 19.6 min, t_R major = 24.1 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	19.502	27.810	21.588	777.864	15.027
2	21.657	55.843	43.348	1709.710	33.028
3	24.149	19.679	15.276	686.547	13.263
4	56.119	25.492	19.788	2002.349	38.682



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	19.611	14.304	1.314	379.654	0.989
2	21.953	794.109	72.950	27484.262	71.571
3	24.122	268.077	24.627	9395.403	24.466
4	55.576	12.074	1.109	1141.859	2.973


Dimethyl 2-((3a*R*,10*R*)-7,9-dichloro-3,3a,4,10-tetrahydrobenzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (5m**)**




Following the general procedure, the title compound **5m** was obtained after FC (petane-EtOAc 6:1) as a white solid (58%) and a 2.9:1 mixture of diastereoisomers (80% ee each): ¹H NMR (300 MHz, CDCl₃): δ = 7.28 (d, *J* = 2.1 Hz, 1H, major), 7.25 (d, *J* = 2.2 Hz, 1H, minor), 7.04 (d, *J* = 2.1 Hz, 1H, major), 6.99 (d, *J* = 2.1 Hz, 1H, minor), 5.37 (d, *J* = 11.7 Hz, 1H, minor),


5.31 (d, $J = 9.9$ Hz, 1H, major), 4.58 (dd, $J = 11.5$, 6.6 Hz, 1H, minor), 4.47 (dd, $J = 11.1$, 8.6 Hz, 2H, minor), 4.35 – 4.21 (m, 2H, major), 4.21 (d, $J = 9.0$ Hz, 2H, major), 4.04 (dd, $J = 8.6$, 6.8 Hz, 1H, major), 3.90 (t, $J = 8.5$ Hz, 1H, minor), 3.81 (s, 3H, major), 3.78 (s, 1H, minor), 3.59 (s, 1H, minor), 3.54 (s, 3H, major), 3.50 – 3.29 (m, 1H, major + 1H, minor); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): Major isomer: $\delta = 167.7$, 167.0, 157.6, 156.8, 135.8, 135.3, 128.7, 126.9, 122.6, 72.6, 71.2, 54.9, 53.2, 52.8, 48.2, 37.5; Minor isomer: $\delta = 166.3$, 163.8, 156.4, 155.1, 137.0, 135.0, 129.4, 126.5, 122.2, 71.4, 71.3, 53.5, 53.3, 52.7, 48.5, 40.5.

The major diastereomer could be isolated: $^1\text{H NMR}$ (400 MHz, CDCl_3): $\delta = 7.28$ (d, $J = 2.1$ Hz, 1H), 7.03 (dd, $J = 2.1$, 0.5 Hz, 1H), 5.30 (d, $J = 9.7$ Hz, 0H), 4.31 (d, $J = 9.8$ Hz, 1H), 4.27 (dd, $J = 9.8$, 8.6 Hz, 1H), 4.21 (d, $J = 1.1$ Hz, 1H), 4.19 (d, $J = 2.6$ Hz, 1H), 4.03 (dd, $J = 8.6$, 6.8 Hz, 1H), 3.80 (s, 3H), 3.54 (s, 3H), 3.46 – 3.32 (m, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): $\delta = 167.7$, 167.0, 157.6, 156.8, 135.8, 135.3, 128.6, 126.9, 122.6, 72.6, 71.2, 54.9, 53.2, 52.8, 48.2, 37.5; **HRMS** (ESI^+) calculated for $\text{C}_{16}\text{H}_{15}\text{Cl}_2\text{NO}_6 + \text{Na}^+ [\text{M} + \text{Na}]^+$: $m/z = 410.0169$ found 410.0166; **IR**: ν_{max} 3081, 2954, 2888, 1736, 1586, 1558, 1435, 1406, 1370, 1334, 1297, 1258, 1238, 1194, 1151, 1089, 1011, 914, 882, 842, 803, 731, 650; **HPLC**: IA, Pentane:*i*-PrOH 90:10, $F = 1.0$ mL/min, $\lambda = 230$ nm: Major isomer: t_{R} major = 17.6 min, t_{R} minor = 24.1 min; Minor isomer: t_{R} minor = 13.1 min, t_{R} major = 14.5 min.







Dimethyl 2-((3*aS*,10*R*)-5-benzoyl-3*a*,4,5,10-tetrahydro-3*H*-benzo[*b*]isoxazolo[3,4-*e*]azepin-10-yl)malonate (5n**)**



Following the general procedure, the title compound **5n** was obtained after FC (petane-EtOAc 4:1→2:1) as a white solid (60%) and a 3.6:1 mixture of diastereoisomers (95% ee each). ¹H NMR (300 MHz, CDCl₃): δ = 7.51 (d, *J* = 7.8 Hz, 2H, minor), 7.45 – 7.38 (m, 2H, major), 7.36 – 7.11 (m, 6H, major, + 6 H, minor), 7.13 – 6.97 (m, 1H, major, + 1H, minor), 6.75 (d, *J* = 7.7 Hz, 1H, major), 6.66 (d, *J* = 7.8 Hz, 1H, minor), 5.36 (dd, *J* = 13.1, 6.5 Hz, 1H, major), 5.34 – 5.23 (m, 1H, minor), 5.05 (d, *J* = 12.6 Hz, 1H, major), 4.88 (d, *J* = 12.4 Hz, 1H, minor), 4.74 (d, *J* = 12.6 Hz, 1H, major), 4.52 (dd, *J* = 10.7, 8.2 Hz, 1H, major), 4.34 (d, *J* = 12.5 Hz, 1H, minor), 4.10 – 3.97 (m, 3H, minor), 3.92 – 3.84 (m, 1H, major), 3.82 (s, 3H, major), 3.76 (s, 3H, minor), 3.76 (s, 3H, major), 3.68 (s, 3H, minor), 2.82 (t, *J* = 12.3 Hz, 1H, minor), 2.71 (dd, *J* = 13.0, 11.6 Hz, 1H, major); ¹³C NMR (100 MHz, CDCl₃): Major isomer: δ = 169.7 (2C), 167.7, 167.7, 157.3, 143.9, 134.8, 133.8, 130.4, 129.4, 129.3, 128.9, 128.7, 128.5, 128.0, 125.1, 71.6, 53.6, 53.4, 52.1, 50.8, 49.9, 39.8; Minor isomer: δ = 166.9, 166.8, 158.4, 156.9, 143.1, 134.1, 131.7, 130.7, 130.0, 129.3, 128.9, 128.8, 128.6, 128.1, 128.1, 127.8, 72.2, 60.5, 53.9, 53.4, 52.9, 50.5, 48.6; HRMS (ESI⁺) calculated for C₂₃H₂₂NO₆+Na⁺ [M+Na]⁺: *m/z* = 445.1370, found 445.1369; IR: ν_{max} 1745, 1725, 1649, 1602, 1579, 1490, 1449, 1435, 1395, 1345, 1320, 1294, 1275, 1264, 1199, 1151, 970, 926, 894, 875, 789, 777, 728, 708; HPLC: IC, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm: Major isomer: *t*_R minor = 51.9 min, *t*_R major = 184.4min; Minor isomer: *t*_R minor = 79.5 min, *t*_R major = 91.8 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	50.921	29.969	59.735	4485.035	33.094
2	77.812	8.404	16.752	2242.413	16.546
3	91.301	3.433	6.842	2336.524	17.241
4	187.881	8.364	16.671	4488.320	33.119




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	51.515	2.323	6.069	386.970	1.905
2	79.465	0.587	1.533	155.437	0.765
3	91.817	8.708	22.750	5862.489	28.853
4	184.371	26.659	69.648	13913.712	68.478

Dimethyl 2-((3a*S*,10*R*)-5-(4-toluensulfonyl)-3a,4,5,10-tetrahydro-3*H*-benzo[*b*]isoxazolo[3,4-*e*]azepin-10-yl)malonate (5o**)**




Following the general procedure, the title compound **5o** was obtained after FC (petane-EtOAc 2:1) as a white solid (57%) and a 2.3:1 mixture of diastereoisomers (97% ee each). ¹H NMR (300 MHz, CDCl₃): δ = 7.84 (d, *J* = 8.3 Hz, 2H minor), 7.78 (d, 8.3 Hz, 2H major), 7.50 (dd, *J* = 7.6, 1.8 Hz, 1H minor), 7.44 – 7.10 (m, 6H major + 4H minor), 6.88 (dd, *J* = 7.8, 1.5 Hz, 1H minor), 4.83 – 4.53 (m, 3H major + 2H minor), 4.51 – 4.22 (m, 2H major + 1H minor), 4.01 – 3.83 (m, 1H major + 2H minor), 3.79 (d, *J* = 3.2 Hz, 1H minor), 3.77 (s, 3H minor), 3.74 (s, 3H major), 3.67 (s, 3H major), 3.61 (s, 3H minor), 3.04 – 2.83 (m, 1H major + 1H minor), 2.48 (s, 3H minor), 2.44 (s, 3H major); ¹³C NMR (75 MHz, CDCl₃): Major isomer: δ = 167.6, 167.4, 157.6, 144.1, 140.1, 138.3, 136.0, 133.8,

130.2, 129.9, 129.6, 129.4, 128.7, 127.3, 125.1, 71.3, 53.3, 52.8, 52.2, 51.8, 50.5, 39.1, 21.8; Minor isomer: δ = 167.6, 167.3, 157.1, 144.4, 140.3, 138.5, 136.0, 134.7, 130.3, 129.9, 129.5, 129.4, 128.6, 127.4, 127.2, 71.7, 53.5, 53.2, 44.6, 21.8; **HRMS** (ESI⁺) calculated for C₂₃H₂₄N₂O₇S+Na⁺ [M+Na]⁺: m/z = 495.1196, found 495.1190; **IR**: ν_{\max} 3291; 2954, 2924, 2850, 2361, 2343, 2257, 1755, 1732, 1599, 1553, 1493, 1452, 1435, 1344, 1304, 1241, 1157, 1089, 1018, 912, 880; **HPLC**: IC, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm: Major isomer: t_R minor = 72.5 min, t_R major = 317.2 min; Minor isomer: t_R major = 94.6 min, t_R minor = 167.0 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	69.158	163.469	67.133	33431.914	42.198
2	94.111	22.210	9.121	7234.951	9.132
3	162.512	17.993	7.389	7972.649	10.063
4	314.142	39.828	16.356	30586.051	38.606




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	72.526	0.616	2.041	164.617	1.139
2	94.604	16.912	56.063	4883.356	33.799
3	167.015	0.191	0.633	96.068	0.665
4	317.198	12.447	41.263	9304.162	64.397


(R)-Dimethyl 2-(4,10-dihydrobenzo[6,7]oxepino[4,3-c]isoxazol-10-yl)malonate (5p)



Following the general procedure, the title compound **5p** was obtained after FC (petane-EtOAc 4:1) as a white solid (99%, 96% ee). $[\alpha]_D^{20} = +119$ (*c* 2.27, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 1.1 Hz, 1H), 7.39 (dd, *J* = 7.1, 1.5 Hz, 1H), 7.30 (ddd, *J* = 8.1, 7.3, 1.7 Hz, 1H), 7.12 (td, *J* = 7.8, 7.4, 1.1 Hz, 2H), 5.40 (dd, *J* = 14.6, 1.2 Hz, 1H), 4.93 (dd, *J* = 11.2, 0.8 Hz, 1H), 4.81 (dd, *J* = 14.6, 1.4 Hz, 1H), 4.53 (d, *J* = 11.2 Hz, 1H), 3.67 (s, 3H), 3.54 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.5, 167.4, 158.9, 157.4, 153.3, 132.0, 131.3, 130.3, 125.5, 123.0, 116.1, 65.9, 56.2, 52.9, 52.6, 41.3; HRMS (ESI⁺) calculated for C₁₆H₁₅NO₆+Na⁺ [M+Na]⁺: *m/z* = 340.0792, found 340.0788; IR: ν_{max} 3118, 3005, 2955, 2873, 1734, 1601, 1582, 1488, 1457, 1434, 1419, 1261, 1238, 1148, 1106, 1013, 894, 782; HPLC: OJ-H, Pentane:*i*-PrOH 85:15, F = 1.0 mL/min, λ = 230 nm, *t*_R major (*R*) = 25.2 min, *t*_R minor (*S*) = 32.8 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	25.443	43.143	48.776	2928.793	42.181
2	31.303	45.308	51.224	4014.544	57.819



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	25.193	154.763	98.657	10558.085	98.114
2	32.752	2.107	1.343	202.923	1.886

(R)-Dimethyl 2-(8-methyl-4,10-dihydrobenzo[6,7]oxepino[4,3-c]isoxazol-10-yl)malonate (5q)





Following the general procedure, the title compound **5q** was obtained after FC (petane-EtOAc 6:1) as a white solid (55%, 95% ee). $[\alpha]_D^{20} = +122$ (*c* 1.24, CHCl₃); **¹H NMR** (300

MHz, CDCl₃): δ = 8.03 (q, *J* = 1.1 Hz, 1H), 7.12 (dd, *J* = 2.2, 0.9 Hz, 1H), 7.02 (ddd, *J* =


8.1, 2.2, 0.8 Hz, 1H), 6.94 (d, *J* = 8.1 Hz, 1H), 5.31 (dd, *J* = 14.6, 1.2 Hz, 1H), 4.81 (d, *J* = 10.8 Hz, 1H), 4.71 (dd, *J* = 14.6, 1.4 Hz, 1H), 4.46 (d, *J* = 11.2 Hz, 1H), 3.60 (s, 3H), 3.49 (s, 3H), 2.23 (s, 3H); **¹³C NMR** (75

MHz, CDCl₃): δ = 167.6, 167.5, 159.1, 155.1, 153.2, 135.1, 131.7, 131.6, 130.7, 122.6, 116.2, 65.9, 56.1, 52.8, 52.6, 41.3, 20.9; **HRMS** (ESI⁺) calculated for C₁₇H₁₇NO₆+Na⁺ [M+Na]⁺: *m/z* = 354.0948, found 354.0948;

IR: ν_{\max} 3132, 3005, 2956, 2921, 2876, 2361, 2343, 1757, 1729, 1606, 1499, 1427, 1420, 1263, 1242, 1232, 1218, 1143, 1123, 1105, 1011, 881, 843, 828; **HPLC**: IA, Pentane:*i*-PrOH 90:10, *F* = 1.0 mL/min, λ = 230 nm: *t_R* major = 19.4 min, *t_R* minor = 15.6 min.



(R)-Dimethyl 2-(8-methoxy-4,10-dihydrobenzo[6,7]oxepino[4,3-c]isoxazol-10-yl)malonate (5r)



Following the general procedure, the title compound **5r** was obtained after FC (petane-

EtOAc 6:1) as a white solid (56%, 94% ee). $[\alpha]_D^{20} = +109$ (c 1.59, CHCl_3); $^1\text{H NMR}$

(300 MHz, CDCl_3): δ = 8.10 (d, J = 1.0 Hz, 1H), 7.04 (d, J = 8.7 Hz, 1H), 6.91 (d,

J = 3.0 Hz, 1H), 6.79 (dd, J = 8.7, 3.0 Hz, 1H), 5.34 (dd, J = 14.5, 1.1 Hz, 1H), 4.87 (dd, J = 11.2, 0.8 Hz, 1H),

4.76 (dd, J = 14.5, 1.4 Hz, 1H), 4.53 (d, J = 11.2 Hz, 1H), 3.76 (s, 3H), 3.66 (s, 3H), 3.57 (s, 3H); $^{13}\text{C NMR}$



(75 MHz, CDCl_3): δ = 167.5, 167.4, 158.9, 156.6, 153.3, 150.9, 132.7, 123.6, 116.2, 116.0, 115.2, 66.0, 56.1,

55.8, 52.9, 52.7, 41.4; **HRMS** (ESI^+) calculated for $\text{C}_{17}\text{H}_{17}\text{NO}_7 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: m/z = 370.0897, found


370.0892; **IR**: ν_{max} 3017, 2958, 2833, 2362, 2343, 1761, 1740, 1615, 1601, 1583, 1495, 1431, 1419, 1291,

1236, 1221, 1204, 1193, 1167, 1150, 1118, 1108, 1038, 1028, 1014, 925, 892, 830, 674, 665; **HPLC**: IA,


Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: t_R major = 30.6 min, t_R minor = 25.0 min.




(R)-Dimethyl 2-(8-chloro-4,10-dihydrobenzo[6,7]oxepino[4,3-c]isoxazol-10-yl)malonate (5s)



Following the general procedure, the title compound **5s** was obtained after FC (petane-EtOAc 8:1) as a white solid (56%, 93% ee). $[\alpha]_D^{20} = +94$ (c 0.76, CHCl_3); $^1\text{H NMR}$ (300 MHz, CDCl_3): δ = 8.13 (d, J = 1.1 Hz, 1H), 7.40 (d, J = 2.6 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.07 (d, J = 8.5 Hz, 1H), 5.40 (dd, J = 14.6, 1.2 Hz, 1H), 4.93 – 4.84 (m, 1H), 4.79 (dd, J = 14.6, 1.4 Hz, 1H), 4.48 (d, J = 11.1 Hz, 1H), 3.67 (s, 3H), 3.60 (s, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ = 167.3, 167.2, 158.4, 155.9, 153.5, 133.7, 131.2, 130.6, 130.2, 124.4, 115.8, 66.1, 56.0, 53.0, 52.8, 41.0; **HRMS** (ESI^+) calculated for $\text{C}_{16}\text{H}_{14}\text{ClNO}_6 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: m/z = 374.0402, found 374.0398; **IR**: ν_{max} 2978, 2958, 2923, 2852, 2358, 1756, 1733, 1601, 1487, 1458, 1443, 1435, 1417, 1326, 1300, 1262, 1175, 1153, 1116, 1102, 1007, 900, 890, 841, 681, 667, 608, 592; **HPLC**: IA, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm: t_R major = 28.2 min, t_R minor = 24.5 min.




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	24.611	37.108	56.290	3304.087	46.277
2	28.202	28.815	43.710	3835.777	53.723




#	Meas. Ret. Time	Height	Height %	Area	Area %
1	24.468	4.865	5.362	471.713	4.372
2	28.162	85.863	94.638	10316.749	95.628

Proposed mechanism for the formation of conjugated nitriles **6** side-products

Only in the cases of the F, Br and Cl substituted derivatives **4**, nitriles **6** were formed and isolated as side-products. The formation of **6** can be rationalized by the relative higher acidity of the benzylic position in these compounds due to the electron-withdrawing nature of the halogen substituents. Subsequently, we propose that after the formation of the nitrile oxide **11**, under the basic conditions employed, the malonate moiety might also be deprotonated to form the corresponding enolate **12**. This could now undergo a proton shift in the cases that the benzylic proton has the appropriate acidity, leading to the ethenone oxime **13**. Finally, the expulsion of the hydroxyl group would lead to the observed unsaturated nitrile **6**.



Dimethyl 2-((2-(allyloxy)-5-fluorophenyl)(cyano)methylene)malonate (**6k**)




The title compound **6k** was obtained after FC (petane-EtOAc 5:1) as yellow oil (27%).

¹H NMR (300 MHz, CDCl₃): δ = 7.11 (ddd, *J* = 9.1, 7.8, 3.1 Hz, 1H), 7.01 (dd, *J* = 8.2, 3.1 Hz, 1H), 6.02 (ddt, *J* = 17.3, 10.5, 5.2 Hz, 1H), 5.40 (dq, *J* = 17.3, 1.5 Hz, 1H), 5.30 (dq, *J* = 10.6, 1.4 Hz, 1H), 4.59 (dt, *J* = 5.3, 1.6 Hz, 2H), 3.94 (s, 3H), 3.66 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃):

δ = 163.1, 161.9, 156.6 (d, ¹*J* = 242.6 Hz), 152.2 (d, ³*J* = 2.8 Hz), 139.6, 132.2, 122.0 (d, ⁴*J* = 1.3 Hz), 121.9 (d, ⁴*J* = 1.5 Hz), 118.7 (d, ²*J* = 22.9 Hz), 118.5, 116.6 (d, ²*J* = 25.2 Hz), 114.8, 114.3 (d, ³*J* = 8.1 Hz), 70.5, 53.7, 53.1; **¹⁹F NMR** (282 MHz, CDCl₃): δ = -121.90; **HRMS** (ESI⁺) calculated for C₁₆H₁₄FNO₅+Na⁺ [M+Na]⁺: *m/z* = 342.0748, found 342.0754; **IR**: ν_{max} 2363, 2343, 1736, 1612, 1590, 1493, 1456, 1436, 1426, 1371, 1303, 1256, 1194, 1180, 1152, 1126, 1083, 1028, 994, 935, 878, 843, 813, 750.

Dimethyl 2-((2-(allyloxy)-5-bromophenyl)(cyano)methylene)malonate (**6l**)




The title compound **6l** was obtained after FC (petane-EtOAc 5:1) as a yellow oil (34%).

¹H NMR (300 MHz, CDCl₃): δ = 7.49 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.38 (d, *J* = 2.4 Hz, 1H), 6.82 (d, *J* = 8.9 Hz, 1H), 6.00 (ddt, *J* = 17.3, 10.4, 5.1 Hz, 1H), 5.40 (dq, *J* = 17.3, 1.6 Hz, 1H), 5.31 (dq, *J* = 10.6, 1.4 Hz, 1H), 4.60 (dt, *J* = 5.2, 1.6 Hz, 2H), 3.94 (s, 3H), 3.67 (s, 3H); **¹³C NMR** (75 MHz, CDCl₃):

δ = 163.1, 161.8, 155.0, 139.6, 135.2, 132.3, 131.9, 122.7, 121.7, 118.6, 114.8, 114.6, 113.0, 70.1, 53.7, 53.1; **HRMS** (ESI⁺) calculated for C₁₆H₁₄BrNO₅+Na⁺ [M+Na]⁺: *m/z* = 401.9948, found 401.9951; **IR**: ν_{max} 2951, 1779, 1735, 1615, 1591, 1483, 1455, 1435, 1400, 1371, 1264, 1242, 1146, 1121, 1093, 1026, 990, 931, 813, 764, 722.


Dimethyl 2-((2-(allyloxy)-4,6-dichlorophenyl)(cyano)methylene)malonate (**6m**)



The title compound **6m** was obtained after FC (petane-EtOAc 4:1) as a white solid (25%).

¹H NMR (300 MHz, CDCl₃): δ = 6.95 (d, *J* = 2.0 Hz, 1H), 6.71 (d, *J* = 2.0 Hz, 1H), 5.99 (ddt, *J* = 17.2, 10.7, 5.4 Hz, 1H), 5.62 – 5.03 (m, 2H), 4.52 (dq, *J* = 5.5, 1.5 Hz, 2H), 3.71 (s, 3H), 3.42 (s, 3H); **HRMS** (ESI⁺) calculated for C₁₆H₁₃Cl₂NO₅+Na⁺ [M+Na]⁺: *m/z* = 369.0171, found 369.01714.


Dimethyl 2-((2-(allyloxy)-5-chlorophenyl)(cyano)methylene)malonate (**6s**)




The title compound **6s** was obtained after FC (petane-EtOAc 8:1) as a yellow oil (26%).

¹H NMR (300 MHz, CDCl₃): δ = 7.40 (dd, *J* = 8.9, 2.6 Hz, 1H), 7.29 (d, *J* = 2.5 Hz, 1H), 7.06 (d, *J* = 8.9 Hz, 1H), 4.73 (d, *J* = 2.4 Hz, 2H), 3.94 (s, 3H), 3.69 (s, 3H), 2.57 (t, *J* = 2.4 Hz, 1H); **¹³C NMR** (75 MHz, CDCl₃): δ = 163.0, 161.8, 153.4, 140.0, 132.2, 129.7, 127.0, 122.7, 121.2, 114.8, 114.6, 77.3, 77.1, 56.9, 53.7, 53.2; **HRMS** (ESI⁺) calculated for C₁₆H₁₂ClNO₅+Na⁺ [M+Na]⁺: *m/z* = 356.0296, found 356.0297. **IR**: ν_{max} 3287, 2957, 1733, 1614, 1572, 1484, 1453, 1436, 1405, 1372, 1267, 1249, 1223, 1146, 1104, 1086, 1017, 990, 929, 891, 879, 813, 764, 675, 644, 612.

Synthesis of bioactive compound *ent*-8




2-Hydroxy-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (**14**)



To a suspension of 2,4-dihydroxybenzaldehyde (2.00 g, 14.48 mmol, 1.0 equiv.) and pyridinium-4-toluolsulfonate (35.7 mg, 0.14 mmol, 0.01 equiv.) in 70 mL DCM a solution of dihydropyran (1.45 mL, 15.93 mmol, 1.1 equiv.) in 24 mL DCM was slowly added.

After stirring the reaction mixture for 1.5 h at room temperature, the reaction mixture was washed with saturated NaCl (aq.) and dried over Na₂SO₄ and the solvent removed in vacuo. The residue was purified by column chromatography (pentane-EtOAc: 20:1), affording **14** (2.32 g, 10.42 mmol, 72%) as a colorless oil. **¹H NMR** (400 MHz, CDCl₃): δ = 11.35 (s, 1H), 9.71 (d, *J* = 0.7 Hz, 1H), 7.42 (d, *J* = 8.6 Hz, 1H), 6.64 (dd, *J* = 8.6, 2.3 Hz, 1H), 6.61 (d, *J* = 2.3 Hz, 1H), 5.49 (t, *J* = 3.2 Hz, 1H), 3.81 (ddd, *J* = 11.3, 9.8, 3.1 Hz, 1H), 3.62 (dtd, *J* = 11.4, 4.1, 1.5 Hz, 1H), 1.97 (dddd, *J* = 13.7, 12.0, 6.9, 3.2 Hz, 1H), 1.86 (ddd, *J* = 6.7, 4.6, 3.2 Hz, 2H), 1.77 – 1.63 (m, 2H), 1.65 – 1.52 (m, 1H); **¹³C NMR** (101 MHz, CDCl₃): δ = 194.6, 164.4, 164.2, 135.4, 115.8, 109.5, 103.7, 96.3, 62.3, 30.0, 25.0, 18.5; **HRMS** (ESI⁺): calculated for C₁₂H₁₄O₄+Na⁺ [M+Na]⁺: *m/z* = 245.0784, found 245.0790.

2-(Prop-2-yn-1-yloxy)-4-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde (**15**)




An ordinary vial equipped with a magnetic stirring bar was charged with **14** (2.23 g, 10.03 mmol, 1.0 equiv.), K₂CO₃ (1.53 g, 11.04 mmol, 1.1 equiv.) and DMF (15 mL, 0.6 M). To the stirring solution, propargyl bromide (80%, 1.23 mL, 11.04 mmol, 1.1 equiv.) was added dropwise. After stirring the solution for 5 h water was added and the mixture extracted 3 times with DCM. The combined organic phases were dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography (pentane-EtOAc: 20:1) to obtain **15** (2.46 g, 9.44 mmol, 94%) as a light yellow oil. ¹H NMR (300 MHz, CD₂Cl₂): δ = 10.28 (d, *J* = 0.8 Hz, 1H), 7.76 (d, *J* = 8.5 Hz, 1H), 6.87 – 6.57 (m, 2H), 5.51 (t, *J* = 3.1 Hz, 1H), 4.82 (d, *J* = 2.4 Hz, 2H), 3.83 (ddd, *J* = 11.4, 9.6, 3.3 Hz, 1H), 3.61 (dtd, *J* = 11.5, 4.1, 1.4 Hz, 1H), 2.66 (t, *J* = 2.4 Hz, 1H), 2.06 – 1.92 (m, 1H), 1.92 – 1.79 (m, 2H), 1.77 – 1.43 (m, 4H); ¹³C NMR (75 MHz, CD₂Cl₂): δ = 188.3, 164.1, 161.9, 130.5, 120.4, 110.0, 101.8, 97.1, 78.2, 76.7, 62.7, 57.0, 30.6, 25.6, 19.1; HRMS (ESI⁺): calculated for C₁₅H₁₆O₄+Na⁺ [M+Na]⁺: *m/z* = 283.0941, found 283.0944.

(E)-2-(4-(2-Nitrovinyl)-3-(prop-2-yn-1-yloxy)phenoxy)tetrahydro-2H-pyran (**16**) and (E)-4-(2-nitrovinyl)-3-(prop-2-yn-1-yloxy)phenol (**2t**)


Aldehyde **15** (1.30 g, 4.99 mmol, 1.0 equiv.) was treated with nitromethane (3.23 mL, 60.34 mmol, 12.1 equiv.), acetic acid (828 μL, 14.47 mmol, 2.9 equiv.) and NH₄OAc (846 mg, 10.98 mmol, 2.2 equiv.) at rt under ultrasound irradiation for 3 h. The corresponding nitroolefins **16** (1.07 g, 3.54 mmol, 71%) and **2t** (0.31 g, 1.39 mmol, 28%) were then isolated by column chromatography (pentane-EtOAc: 10:1→4:1).

(E)-2-(4-(2-Nitrovinyl)-3-(prop-2-yn-1-yloxy)phenoxy)tetrahydro-2H-pyran (**16**)



Not stable under slightly acidic conditions! ¹H NMR (300 MHz, CDCl₃): δ = 8.04 (d, *J* = 13.6 Hz, 1H), 7.75 (d, *J* = 13.5 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 1H), 6.76 – 6.60 (m, 2H), 5.43 (t, *J* = 3.0 Hz, 1H), 4.74 (d, *J* = 2.5 Hz, 2H), 3.79 (ddd, *J* = 11.2, 9.7, 3.2 Hz, 1H), 3.57 (dtd, *J* = 11.4, 4.0, 1.6 Hz, 1H), 2.53 (t, *J* = 2.4 Hz, 1H), 2.01 – 1.87 (m, 1H), 1.82 (dt, *J* = 5.6, 3.6 Hz, 2H), 1.75 – 1.41 (m, 4H); ¹³C NMR (75 MHz, CDCl₃): δ = 161.8, 159.0, 136.6, 135.5, 134.0, 113.3, 109.8, 101.7, 96.6, 77.4, 76.8, 62.3, 56.4, 30.2, 25.1, 18.6. HRMS (ESI⁺) calculated for C₁₆H₁₇NO₅+Na⁺ [M+Na]⁺: *m/z* = 326.0999, found 326.0996.


(E)-4-(2-Nitrovinyl)-3-(prop-2-yn-1-yloxy)phenol (**2t**)



To a solution of nitroolefin **16** (1.00 g, 3.30 mmol, 1.0 equiv.) in MeOH (83 mL, 0.04 M), *p*-TsOH (56.6 mg, 0.33 mmol, 0.1 equiv.) was added and stirred at rt for 1 h until completion of reaction (followed by TLC). The


residue was purified by column chromatography (pentane-EtOAc: 4:1), affording **2t** as a yellow-orange solid (0.70 g, 3.20 mmol, 97%). ¹H NMR (300 MHz, DMSO-*d*₆) δ = 10.65 (s, 1H), 8.12 (d, *J* = 13.4 Hz, 1H), 7.98 (d, *J* = 13.4 Hz, 1H), 7.66 (d, *J* = 8.5 Hz, 1H), 6.60 (d, *J* = 2.2 Hz, 1H), 6.51 (dd, *J* = 8.5, 2.2 Hz, 1H), 4.95 (d, *J* = 2.4 Hz, 2H), 3.70 (t, *J* = 2.3 Hz, 1H), 3.38 (br.s, 1H); ¹³C NMR (75 MHz, DMSO): δ = 163.4, 159.2, 135.4, 134.8, 134.0, 110.2, 109.6, 100.7, 79.1, 78.6, 56.2. HRMS (ESI⁺): calculated for C₁₁H₉NO₄+Na⁺ [M+Na]⁺: *m/z* = 242.0424, found 242.0429.

(*E*)-4-((4-Bromobenzyl)oxy)-1-(2-nitrovinyl)-2-(prop-2-yn-1-yloxy)benzene (7t)




To a solution of nitroolefin **2t** (600 mg, 2.74 mmol, 1.0 equiv.) and 4-bromobenzyl bromide (685 mg, 2.74 mmol, 1.0 equiv.) in acetone (8.5 mL, 0.33 M), K₂CO₃ (379 mg, 2.74 mmol, 1.0 equiv.) and TBAB (177 mg, 0.55 mmol, 0.2 equiv.) were added and stirred at rt for 4 h until completion of reaction (followed by TLC). The residue was purified by column chromatography (pentane-EtOAc: 4:1) affording **7t** as a yellow-orange solid (0.70 g, 3.20 mmol, 97%). ¹H NMR (300 MHz, CDCl₃): δ = 8.09 (d, *J* = 13.6 Hz, 1H), 7.80 (d, *J* = 13.5 Hz, 1H), 7.59 – 7.46 (m, 2H), 7.40 (d, *J* = 8.5 Hz, 1H), 7.35 – 7.27 (m, 2H), 6.70 – 6.60 (m, 2H), 5.08 (s, 2H), 4.79 (d, *J* = 2.4 Hz, 2H), 2.58 (t, *J* = 2.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ = 163.0, 159.0, 136.6, 135.3, 135.0, 134.2, 132.1 (2C), 129.3 (2C), 122.5, 113.2, 107.8, 100.8, 77.3, 77.0, 69.8, 56.4. HRMS (ESI⁺) calculated for C₁₈H₁₄BrNO₄+Na⁺ [M+Na]⁺: *m/z* = 409.9998, found 410.0003.

Dimethyl (*S*)-2-(7-((4-bromobenzyl)oxy)-4H,10H-benzo[6,7]oxepino[4,3-*c*]isoxazol-10-yl)malonate (*ent*-5t)





An ordinary vial equipped with a magnetic stirring bar was charged with catalyst **1e'** (10 mol%), malonate **3** (41.4 μL, 0.36 mmol, 1.2 equiv.), nitroolefin **7t** (77.6 mg, 0.30 mmol, 1.0 equiv.) and *o*-xylene (1.5 mL) at rt. The stirring was maintained at rt for 7 d. The crude reaction mixture was directly charged onto silica-gel and purified by column chromatography (pentane-EtOAc: 6:1) to afford compound **ent-4t** (93.4 mg, 0.18 mmol, 60%). ¹H NMR (300 MHz, CDCl₃): δ = 7.56 – 7.45 (m, 2H), 7.31 – 7.26 (m, 2H), 7.06 (d, *J* = 8.4 Hz, 1H), 6.60 (d, *J* = 2.3 Hz, 1H), 6.48 (dd, *J* = 8.5, 2.4 Hz, 1H), 5.00 (dd, *J* = 13.0, 9.2 Hz, 1H), 4.95 (s, 2H),

4.85 (dd, $J = 13.0, 4.6$ Hz, 1H), 4.71 (d, $J = 2.4$ Hz, 2H), 4.33 (td, $J = 9.5, 4.6$ Hz, 1H), 4.14 (d, $J = 10.0$ Hz, 1H), 3.75 (s, 3H), 3.51 (s, 3H), 2.55 (t, $J = 2.4$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 168.4, 167.7, 159.7, 156.5, 135.7, 131.9$ (2C), 131.6, 129.3 (2C), 122.2, 117.0, 106.5, 101.2, 77.9, 76.3, 76.3, 69.5, 56.3, 53.0, 52.8, 52.7, 39.9; **HRMS** (ESI^+) calculated for $\text{C}_{23}\text{H}_{22}\text{BrNO}_8 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 544.0402$, found 544.0394.




The nitro compound **ent-4t** (104.1 mg, 0.2 mmol, 1.0 equiv.) and DMAP (4.9 mg, 0.04 mmol, 0.2 equiv.) were dissolved in freshly distilled toluene (1.0 mL) and heated to 90 °C. To the hot reaction mixture, a solution of Boc_2O in toluene (0.5 M, 1.0 mL, 2.5 equiv.) was added over 20 min. The reaction was then allowed to proceed for further 3.5 h at 90 °C. After cooling to room temperature, the crude reaction mixture was directly charged onto silica-gel and purified by column chromatography to afford the titled compound **ent-5t** (58.2 mg, 0.12 mmol, 58%, 97% ee). ^1H NMR (300 MHz, CDCl_3): $\delta = 8.11$ (d, $J = 1.0$ Hz, 1H), 7.50 (d, $J = 8.4$ Hz, 2H), 7.28 (dd, $J = 8.4, 5.2$ Hz, 3H), 6.86 – 6.62 (m, 2H), 5.39 (dd, $J = 14.6, 1.2$ Hz, 1H), 4.97 (s, 2H), 4.88 (d, $J = 11.1$ Hz, 1H), 4.79 (dd, $J = 14.7, 1.4$ Hz, 1H), 4.46 (d, $J = 11.1$ Hz, 1H), 3.67 (s, 3H), 3.56 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): $\delta = 167.6, 167.5, 159.9, 159.1, 158.4, 153.3, 135.6, 132.0, 131.9$ (2C), 129.2 (2C), 124.4, 122.2, 116.1, 111.6, 109.7, 69.5, 66.0, 56.4, 52.9, 52.7, 40.6; **HRMS** (ESI^+) calculated for $\text{C}_{23}\text{H}_{20}\text{BrNO}_7 + \text{Na}^+$ $[\text{M} + \text{Na}]^+$: $m/z = 524.0315$, found 524.0336; **IR** (ATR): ν_{max} 2954, 2875, 1736, 1611, 1580, 1495, 1456, 1434, 1415, 1287, 1260, 1155, 1118, 1104, 1071, 1022, 1011, 946, 891, 805, 711, 559; **HPLC**: IA, Pentane:i-PrOH 70:30, $F = 1.0$ mL/min, $\lambda = 230$ nm, t_{R} major (*S*) = 12.3 min, t_{R} minor (*R*) = 22.2 min.







Methyl (S)-2-(7-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methoxy)-4H,10H-benzo[6,7]oxepino[4,3-c]isoxazol-10-yl)acetate (*ent*-8)



To a solution of *ent*-5t (50.2 mg, 0.1 mmol, 1.0 equiv.), boronic acid (22.8 mg, 0.12 mmol, 1.2 equiv.) and Na₂CO₃ (26.5 mg, 0.25 mmol, 2.5 equiv.) in dry 1,4-dioxane (0.4 mL), Pd(PPh₃)₄ (11.6 mg, 0.01 mmol, 10 mol%) and dest. water (50 µL) were added. The reaction mixture was heated at 150 °C for 2d. The crude reaction mixture was directly charged onto silica-gel and purified by column chromatography (pentane-EtOAc: 4:1) to afford the titled compound *ent*-8 as a white solid (50.4 mg, 0.99 mmol, 99%, 90% ee). $[\alpha]_D^{20} = -108$ (*c* 0.98, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ = 8.10 (s, 1H), 7.70 (s, 4H), 7.65 – 7.59 (m, 2H), 7.55 – 7.50 (m, 1H), 7.23 (d, *J* = 8.5 Hz, 1H), 6.81 (d, *J* = 2.6 Hz, 1H), 6.76 (dd, *J* = 8.4, 2.6 Hz, 1H), 5.28 (dd, *J* = 14.5, 1.1 Hz, 1H), 5.09 (s, 2H), 4.89 (dd, *J* = 14.5, 1.4 Hz, 1H), 4.74 (dd, *J* = 9.0, 6.4 Hz, 1H), 3.63 (s, 3H), 3.18 (dd, *J* = 15.7, 9.0 Hz, 1H), 3.07 (dd, *J* = 15.7, 6.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃): δ = 171.6, 161.2, 159.8, 158.6, 153.0, 144.3 (q, ⁴*J* = 1.3 Hz, 2C), 139.7, 136.8, 130.3, 129.6 (q, ²*J* = 32.6 Hz), 128.2 (2C), 127.7 (2C), 127.5 (2C), 126.3, 125.9 (q, ³*J* = 3.7 Hz, 2C), 124.4 (d, ¹*J* = 272.0 Hz), 116.1, 111.5, 109.9, 70.0, 66.0, 51.9, 39.7, 37.1; HRMS (ESI⁺) calculated for C₂₈H₂₂F₃NO₅+Na⁺ [M+Na]⁺: *m/z* = 532.1342, found 532.1341; IR (ATR): ν_{max} 3119, 2953, 2925, 2856, 2365, 2342, 1736, 1613, 1580, 1496, 1458, 1415, 1358, 1324, 1260, 1160, 1109, 1070, 1023, 1007, 909, 885, 850, 816, 732, 647, 621, 603. HPLC: AD-H, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm, t_R major (*S*) = 25.3 min, t_R minor (*R*) = 22.4 min.



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	21.570	128.415	49.529	4863.388	46.446
2	24.383	130.856	50.471	5607.558	53.554



#	Meas. Ret. Time	Height	Height %	Area	Area %
1	22.386	6.859	5.570	287.303	5.070
2	25.332	116.284	94.430	5378.982	94.930

References:

- (1) B. Vakulya, S. Varga, A. Csámpai, T. Soós, *Org. Lett.* 2005, **7**, 1967.
- (2) J. P. Malerich, K. Hagihara, V. H. Rawal, *J. Am. Chem. Soc.* 2008, **130**, 14416.
- (3) Ł. Albrecht, G. Dickmeiss, F. Cruz Acosta, C. Rodríguez-Esrich, R. L. Davis, K. A. Jørgensen, *J. Am. Chem. Soc.* 2012, **134**, 2543.
- (4) Y.-T. Lee, Y.-J. Jang, S.-e. Syu, S.-C. Chou, C.-J. Lee, W. Lin, *Chem. Commun.* 2012, **48**, 8135.
- (5) K. Hirano, A. T. Biju, I. Piel, F. Glorius, *J. Am. Chem. Soc.* 2009, **131**, 14190.
- (6) F. Miege, C. Meyer, J. Cossy, *Angew. Chem. Int. Ed.* 2011, **50**, 5932.
- (7) K. Ramachandiran, K. Karthikeyan, D. Muralidharan, P. T. Perumal, *Tetrahedron Lett.* 2010, **51**, 3006.
- (8) B. M. Trost, C. Müller, *J. Am. Chem. Soc.* 2008, **130**, 2438.
- (9) J. McNulty, J. A. Steere, S. Wolf, *Tetrahedron Lett.* 1998, **39**, 8013.
- (10) K. Ramachandiran, K. Karthikeyan, T. Nandhakumar, D. Muralidharan, P. T. Perumal, *Synthesis* 2011, 3277.
- (11) T. Shiizu, Y. Hayashi, H. Shibafuchi, K. Teramura, *Bull. Chem. Soc. Jpn.* 1986, **59**, 2827.
- (12) H. R. Kim, H. J. Kim, J. L. Duffy, M. M. Olmstead, K. Ruhlandt-Senge, M. J. Kurth, *Tetrahedron Lett.* 1991, **32**, 4259.
- (13) Y. Basel, A. Hassner, *Synthesis* 1997, 309.

X-Ray ORTEP and data of compound (3a*R*,10*R*)-5a

Formula C₁₆H₁₇NO₆, *M* = 319.31

Colourless crystal, 0.25 x 0.10 x 0.08 mm


a = 8.2054(1), *b* = 10.5740(1), *c* = 8.6556(1) Å, β = 95.960(1)

V = 746.9(1) Å³, ρ_{calc} = 1.420 gcm⁻³, μ = 0.923 mm⁻¹

Empirical absorption correction (0.802 ≤ *T* ≤ 0.929)


Z = 2, monoclinic, space group *P*2₁ (No. 4)

λ = 1.54178 Å, *T* = 223(2) K





ω and φ scans, 3697 reflections collected ($\pm h$, $\pm k$, $\pm l$), $[(\sin\theta)/\lambda] = 0.60 \text{ \AA}^{-1}$, 2081 independent ($R_{int} = 0.026$) and 2077 observed reflections [$I > 2\sigma(I)$], 210 refined parameters, $R = 0.030$, $wR^2 = 0.07$, max. (min.) residual electron density 0.09 (-0.10) e.Å⁻³, the hydrogens were calculated and refined as riding atoms. Flack parameter was refined to 0.07(2).



It was possible to measure the crystal by HPLC, showing that the structure corresponds to the major enantiomer (*R,R*) of the major diastereomer pair (*R,R*)/(*S,S*).





NMR Spectra:





S51





S52





S53





S54





S55





S56





S57





S58





S59





S60




S61





S62








S64





S65





S66





S67





S68





S69





S70





S71





S72





S73





S74




S75





S76





S77





S78





S79





S80




S81





S82











S84







S85

















S90





S91










S93





S94











S97





S98





5m (major isomer):





S100





S101





S102





S103





S104





S105




S106





S107




S108





S109








S111





S112





S113



S114



S115



S116

